All Stories

  1. Current and emerging therapies as potential treatment for people with von Willebrand disease

    Article • Expert Review of Hematology, November 2024, Taylor & Francis

    Dr Emmanuel J Favaloro

  2. Innovative Diagnostic Solutions in Hemostasis

    Article • Diagnostics, November 2024, MDPI AG

    Dr Emmanuel J Favaloro

  3. Sticky Platelet Syndrome Revisited?

    Article • Seminars in Thrombosis and Hemostasis, November 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  4. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

    Article • Journal of Thrombosis and Haemostasis, November 2024, Elsevier

    Dr Emmanuel J Favaloro

  5. Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond

    Article • Seminars in Thrombosis and Hemostasis, October 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  6. Welcome to Seminars in Thrombosis and Hemostasis 2025: Toward the Next 50 Years of Publishing and Announcement of New Online Manuscript Submission System

    Article • Seminars in Thrombosis and Hemostasis, October 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  7. Innovative Diagnostic Solutions in Hemostasis

    Article • October 2024, MDPI AG

    Dr Emmanuel J Favaloro

  8. Reflections on World Thrombosis Day 2024

    Article • Thrombosis and Haemostasis, October 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  9. Revisiting the Environmental Impact of Inappropriate Clinical Laboratory Testing: A Comprehensive Overview of Sustainability, Economic, and Quality of Care Outcomes

    Article • The Journal of Applied Laboratory Medicine, October 2024, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  10. Reliability of generative artificial intelligence in identifying the major risk factors for venous thrombosis

    Article • Blood Coagulation & Fibrinolysis, October 2024, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  11. Routine Coagulation

    Article • Clinics in Laboratory Medicine, September 2024, Elsevier

    Dr Emmanuel J Favaloro

  12. Heparin and Posttraumatic Stress Disorder

    Article • Seminars in Thrombosis and Hemostasis, July 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  13. New STH 2023 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

    Article • Seminars in Thrombosis and Hemostasis, July 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  14. Continued harmonization of the international normalized ratio across a large laboratory network: Evidence of sustained low interlaboratory variation and bias after a change in instrumentation

    Article • American Journal of Clinical Pathology, July 2024, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  15. EFLM Task Force Preparation of Labs for Emergencies (TF-PLE) recommendations for reinforcing cyber-security and managing cyber-attacks in medical laboratories

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2024, De Gruyter

    Dr Emmanuel J Favaloro

  16. EFLM Task Force Preparation of Labs for Emergencies (TF-PLE) survey on cybersecurity

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2024, De Gruyter

    Dr Emmanuel J Favaloro

  17. 2023 Eberhard F. Mammen Award Announcements: Part II–Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, July 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  18. COVID-19 vaccination prevents venous thrombosis in patients with SARS-CoV-2 infection and thereafter

    Article • Blood Coagulation & Fibrinolysis, July 2024, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  19. The Role of Viscoelastic Testing in Assessing Hemostasis: A Challenge to Standard Laboratory Assays?

    Article • Journal of Clinical Medicine, June 2024, MDPI AG

    Dr Emmanuel J Favaloro

  20. Should APTT become part of thrombophilia screening?

    Article • Diagnosis, May 2024, De Gruyter

    Dr Emmanuel J Favaloro

  21. Contact Activation: Where Thrombosis and Hemostasis Meet on a Foreign Surface, Plus a Mini-editorial Compilation (“Part XVI”)

    Article • Seminars in Thrombosis and Hemostasis, May 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  22. Prone Position and the Risk of Venous Thrombosis in COVID-19 Patients with Respiratory Failure

    Article • Seminars in Thrombosis and Hemostasis, May 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  23. Performance of direct oral anticoagulant (DOAC) testing by hemostasis laboratories: The Australasian/Asia‐Pacific experience

    Article • International Journal of Laboratory Hematology, April 2024, Wiley

    Dr Emmanuel J Favaloro

  24. The Most Highly Downloaded Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 10 Years in the Making

    Article • Seminars in Thrombosis and Hemostasis, April 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  25. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part IV

    Article • Seminars in Thrombosis and Hemostasis, April 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  26. Laboratory diagnosis of von Willebrand disease: the phenotype

    Article • March 2024, Wiley

    Dr Emmanuel J Favaloro

  27. Editorial Compilation—XV

    Article • Seminars in Thrombosis and Hemostasis, March 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  28. 2024 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, March 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  29. Pearls and Pitfalls in the Measurement of Direct Oral Anticoagulants

    Article • Seminars in Thrombosis and Hemostasis, March 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  30. Variable Performance of D-dimer Testing by Hemostasis Laboratories: The Australasian/Asia-Pacific Experience

    Article • Seminars in Thrombosis and Hemostasis, March 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  31. D-dimer Levels for the exclusion of pulmonary embolism: making sense of international guideline recommendations

    Article • Journal of Thrombosis and Haemostasis, March 2024, Elsevier

    Dr Emmanuel J Favaloro

  32. Testing for the lupus anticoagulant: the good, the bad, and the ugly

    Article • Research and Practice in Thrombosis and Haemostasis, March 2024, Elsevier

    Dr Emmanuel J Favaloro

  33. Venous Thrombosis in Airborne Viral Infections: Is Coronavirus Disease 2019 now Any Different from Influenza?

    Article • Seminars in Thrombosis and Hemostasis, February 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  34. Diagnostic value of D-dimer in differentiating multisystem inflammatory syndrome in Children (MIS-C) from Kawasaki disease: systematic literature review and meta-analysis

    Article • Diagnosis, February 2024, De Gruyter

    Dr Emmanuel J Favaloro

  35. Unfractionated heparin: optimizing laboratory monitoring and reducing unwanted interference in everyday hemostasis test practice

    Article • Polish Archives of Internal Medicine, February 2024, Towarzystwo Internistow Polskich/Polish Society of Internal Medicine

    Dr Emmanuel J Favaloro

  36. Simplified Method for Removing Direct Oral Anticoagulant Interference in Mechanical Coagulation Test Systems—A Proof of Concept

    Article • Journal of Clinical Medicine, February 2024, MDPI AG

    Dr Emmanuel J Favaloro

  37. Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper

    Article • Thrombosis and Haemostasis, February 2024, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  38. Therapeutic drug monitoring of selected direct oral anticoagulants

    Article • January 2024, Elsevier

    Dr Emmanuel J Favaloro

  39. Artificial intelligence in the pre-analytical phase: State-of-the art and future perspectives

    Article • Journal of Medical Biochemistry, January 2024, Centre for Evaluation in Education and Science (CEON/CEES)

    Dr Emmanuel J Favaloro

  40. D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap

    Article • Research and Practice in Thrombosis and Haemostasis, January 2024, Elsevier

    Dr Emmanuel J Favaloro

  41. Recent monthly mortality for pulmonary embolism in the US

    Article • Thrombosis Research, January 2024, Elsevier

    Dr Emmanuel J Favaloro

  42. Vaccine-induced (immune) thrombotic thrombocytopenia (VITT): Diagnosis, guidelines, and reporting

    Article • January 2024, Elsevier

    Dr Emmanuel J Favaloro

  43. von Willebrand Disease

    Article • January 2024, Elsevier

    Dr Emmanuel J Favaloro

  44. Variable Performance of Lupus Anticoagulant Testing: The Australasian/Asia-Pacific Experience

    Article • Seminars in Thrombosis and Hemostasis, November 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  45. Description of an In Vitro Platelet Function Analyzer (PFA-100/PFA-200) 30 Years in the Making

    Article • Seminars in Thrombosis and Hemostasis, October 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  46. Classification Criteria for the Antiphospholipid Syndrome: Not the Same as Diagnostic Criteria for Antiphospholipid Syndrome

    Article • Seminars in Thrombosis and Hemostasis, October 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  47. The Most Highly Cited Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 50 Years in the Making

    Article • Seminars in Thrombosis and Hemostasis, September 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  48. Editorial Compilation XIV

    Article • Seminars in Thrombosis and Hemostasis, September 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  49. Effect of syringe underfilling on the quality of venous blood gas analysis

    Article • Diagnosis, September 2023, De Gruyter

    Dr Emmanuel J Favaloro

  50. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part III

    Article • Seminars in Thrombosis and Hemostasis, August 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  51. Welcome to Seminars in Thrombosis and Hemostasis 2024: 50 Years of Publishing

    Article • Seminars in Thrombosis and Hemostasis, August 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  52. New Seminars in Thrombosis and Hemostasis 2022 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

    Article • Seminars in Thrombosis and Hemostasis, August 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  53. Are Antiphospholipid Antibodies a Surrogate Risk Factor for Thrombosis in Sepsis?

    Article • Seminars in Thrombosis and Hemostasis, July 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  54. Incomplete filling of spray-dried K2EDTA evacuated blood tubes: impact on measuring routine hematological parameters on Sysmex XN-10

    Article • Diagnosis, July 2023, De Gruyter

    Dr Emmanuel J Favaloro

  55. Comparison of 2 ways of performing ristocetin-induced platelet agglutination mixing study for diagnosis of type 2B von Willebrand disease. Response to the publication of Soleimani et al

    Article • Research and Practice in Thrombosis and Haemostasis, July 2023, Elsevier

    Dr Emmanuel J Favaloro

  56. Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources

    Article • Research and Practice in Thrombosis and Haemostasis, July 2023, Elsevier

    Dr Emmanuel J Favaloro

  57. Letter in response to Colpani et al “A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”

    Article • Research and Practice in Thrombosis and Haemostasis, July 2023, Elsevier

    Dr Emmanuel J Favaloro

  58. Results of the first survey of the EFLM Task Force Preparation of Labs for Emergencies (TF-PLE)

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2023, De Gruyter

    Dr Emmanuel J Favaloro

  59. Disruption of Laboratory Activities during the COVID-19 Pandemic: Results of an EFLM Task Force Preparation of Labs for Emergencies (TF-PLE) Survey

    Article • June 2023, MDPI AG

    Dr Emmanuel J Favaloro

  60. Epidemiology and Predisposing Factors of Post-COVID Venous Thrombosis: A Concise Review

    Article • Seminars in Thrombosis and Hemostasis, June 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  61. Effects of Recombinant SARS-CoV-2 Spike Protein Variants on Platelet Morphology and Activation

    Article • Seminars in Thrombosis and Hemostasis, June 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  62. Incomplete filling of spray-dried K2EDTA evacuated blood tubes: impact on measuring routine hematological parameters on Sysmex XN-10

    Article • June 2023, Research Square

    Dr Emmanuel J Favaloro

  63. Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress

    Article • Research and Practice in Thrombosis and Haemostasis, May 2023, Elsevier

    Dr Emmanuel J Favaloro

  64. 2022 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, April 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  65. A multicenter evaluation of the Technoscreen ADAMTS13 activity semi‐quantitative screening test for thrombotic thrombocytopenic purpura diagnosis and exclusion

    Article • International Journal of Laboratory Hematology, April 2023, Wiley

    Dr Emmanuel J Favaloro

  66. Reducing our carbon footprint in the haematology laboratory: A shared responsibility

    Article • International Journal of Laboratory Hematology, March 2023, Wiley

    Dr Emmanuel J Favaloro

  67. 2023 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, March 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  68. To Clot or Not to Clot: Is That the Question?

    Article • Journal of Clinical Medicine, March 2023, MDPI AG

    Dr Emmanuel J Favaloro

  69. Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms

    Article • Research and Practice in Thrombosis and Haemostasis, March 2023, Elsevier

    Dr Emmanuel J Favaloro

  70. Mixing factor Xa and thrombin inhibiting direct oral anticoagulants produces a synergistic prolonging effect on most clotting tests

    Article • International Journal of Laboratory Hematology, February 2023, Wiley

    Dr Emmanuel J Favaloro

  71. The Role of the von Willebrand Factor Collagen-Binding Assay (VWF:CB) in the Diagnosis and Treatment of von Willebrand Disease (VWD) and Way Beyond: A Comprehensive 36-Year History

    Article • Seminars in Thrombosis and Hemostasis, February 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  72. Editorial Compilation—XIII

    Article • Seminars in Thrombosis and Hemostasis, February 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  73. Evolution of Hemostasis Testing: A Personal Reflection Covering over 40 Years of History*

    Article • Seminars in Thrombosis and Hemostasis, February 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  74. Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia

    Article • Seminars in Thrombosis and Hemostasis, January 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  75. Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part IV

    Article • Seminars in Thrombosis and Hemostasis, January 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  76. Welcome to Seminars in Thrombosis & Hemostasis 2023

    Article • Seminars in Thrombosis and Hemostasis, January 2023, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  77. von Willebrand Disease: An Update on Diagnosis and Treatment

    Article • January 2023, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  78. An Overview of Laboratory Testing for Antiphospholipid Antibodies

    Article • January 2023, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  79. Laboratory Testing for Activated Protein C Resistance (APCR): An Update

    Article • January 2023, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  80. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part II

    Article • Seminars in Thrombosis and Hemostasis, December 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  81. Assessment of immunological anti‐platelet factor 4 antibodies for vaccine‐induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients

    Article • Journal of Thrombosis and Haemostasis, December 2022, Elsevier

    Dr Emmanuel J Favaloro

  82. Corrigendum to “A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia” [Pathology (53) (2021) 247–256]

    Article • Pathology, December 2022, Elsevier

    Dr Emmanuel J Favaloro

  83. How often are parenteral anticoagulants administered by parents?

    Article • Journal of Thrombosis and Haemostasis, December 2022, Elsevier

    Dr Emmanuel J Favaloro

  84. Autoimmune Diseases Affecting Hemostasis: A Narrative Review

    Article • International Journal of Molecular Sciences, November 2022, MDPI AG

    Dr Emmanuel J Favaloro

  85. Dedication to Santa Maria Favaloro (1926–2022)

    Article • Seminars in Thrombosis and Hemostasis, November 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  86. The myths behind DOAC measurement: Analyses of prescribing information from different regulatory bodies and a call for harmonization

    Article • Journal of Thrombosis and Haemostasis, November 2022, Elsevier

    Dr Emmanuel J Favaloro

  87. Letter to the Editor: 10-Year Evolution in Worldwide Usage of Anticoagulant Drugs

    Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  88. Toward 50 Years of Seminars in Thrombosis and Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  89. Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part I

    Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  90. Strength of Anticoagulation in Moderate to Severe COVID-19 Illness: In Medio Stat Virtus?

    Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  91. New Seminars in Thrombosis and Hemostasis (STH) 2021 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

    Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  92. Laboratory Diagnosis of von Willebrand Disease (VWD): Geographical Perspectives

    Article • Seminars in Thrombosis and Hemostasis, September 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  93. Harmonizing factor assay-related testing performed in a large laboratory network

    Article • Blood Coagulation & Fibrinolysis, July 2022, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  94. Towards 50 years of platelet function analyser (PFA) testing

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2022, De Gruyter

    Dr Emmanuel J Favaloro

  95. D-dimer: old dogmas, new (COVID-19) tricks

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2022, De Gruyter

    Dr Emmanuel J Favaloro

  96. A Review of Autoimmune Acquired von Willebrand Factor Deficiency in Japan

    Article • Seminars in Thrombosis and Hemostasis, July 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  97. D-dimers—“Normal” Levels versus Elevated Levels Due to a Range of Conditions, Including “D-dimeritis,” Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19

    Article • Seminars in Thrombosis and Hemostasis, July 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  98. Editorial Compilation XII

    Article • Seminars in Thrombosis and Hemostasis, July 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  99. Counting the carbon cost of heparin: an evolving tragedy of the commons?

    Article • The Lancet Haematology, July 2022, Elsevier

    Dr Emmanuel J Favaloro

  100. Getting smart with coagulation

    Article • Journal of Thrombosis and Haemostasis, July 2022, Elsevier

    Dr Emmanuel J Favaloro

  101. Harmonizing platelet function analyzer testing and reporting in a large laboratory network

    Article • International Journal of Laboratory Hematology, June 2022, Wiley

    Dr Emmanuel J Favaloro

  102. Heparin: The Journey from Parenteral Agent to Nasal Delivery

    Article • Seminars in Thrombosis and Hemostasis, June 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  103. 2022 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, June 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  104. A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia

    Article • Blood Advances, June 2022, American Society of Hematology

    Dr Emmanuel J Favaloro

  105. Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study

    Article • Frontiers in Medicine, April 2022, Frontiers

    Dr Emmanuel J Favaloro

  106. Cell-Free DNA, Neutrophil extracellular traps (NETs), and Endothelial Injury in Coronavirus Disease 2019– (COVID-19–) Associated Acute Kidney Injury

    Article • Mediators of Inflammation, April 2022, Hindawi Publishing Corporation

    Dr Emmanuel J Favaloro

  107. “Von Willebrand disease type 2M: Correlation between genotype and phenotype”: Comment from Favaloro

    Article • Journal of Thrombosis and Haemostasis, April 2022, Elsevier

    Dr Emmanuel J Favaloro

  108. 2021 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, April 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  109. Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia

    Article • Pathology, April 2022, Elsevier

    Dr Emmanuel J Favaloro

  110. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin‐induced thrombocytopenia

    Article • Journal of Thrombosis and Haemostasis, April 2022, Elsevier

    Dr Emmanuel J Favaloro

  111. The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer

    Article • Healthcare, March 2022, MDPI AG

    Dr Emmanuel J Favaloro

  112. A multi‐laboratory assessment of lupus anticoagulant assays performed on the ACL TOP 50 family for harmonized testing in a large laboratory network

    Article • International Journal of Laboratory Hematology, March 2022, Wiley

    Dr Emmanuel J Favaloro

  113. Editorial Compilation XI

    Article • Seminars in Thrombosis and Hemostasis, February 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  114. The Benefits of Heparin Use in COVID-19: Pleiotropic Antiviral Activity beyond Anticoagulant and Anti-Inflammatory Properties

    Article • Seminars in Thrombosis and Hemostasis, February 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  115. An Analysis of the Sensitivity of the Activated Partial Thromboplastin Time (APTT) Assay, as Used in a Large Laboratory Network, to Coagulation Factor Deficiencies

    Article • American Journal of Clinical Pathology, February 2022, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  116. Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part III

    Article • Seminars in Thrombosis and Hemostasis, February 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  117. Welcome to Seminars in Thrombosis & Hemostasis 2022

    Article • Seminars in Thrombosis and Hemostasis, February 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  118. Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants

    Article • Research and Practice in Thrombosis and Haemostasis, February 2022, Elsevier

    Dr Emmanuel J Favaloro

  119. Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!

    Article • Research and Practice in Thrombosis and Haemostasis, February 2022, Elsevier

    Dr Emmanuel J Favaloro

  120. Comparing the quality of testing for von Willebrand disease in different geographic localities

    Article • Haemophilia, January 2022, Wiley

    Dr Emmanuel J Favaloro

  121. Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS

    Article • Antibodies, January 2022, MDPI AG

    Dr Emmanuel J Favaloro

  122. Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data

    Article • Blood Advances, January 2022, American Society of Hematology

    Dr Emmanuel J Favaloro

  123. What We Know (and Do not Know) Regarding the Pathogenesis of Pulmonary Thrombosis in COVID-19

    Article • Seminars in Thrombosis and Hemostasis, January 2022, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  124. 2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines

    Article • Research and Practice in Thrombosis and Haemostasis, December 2021, Elsevier

    Dr Emmanuel J Favaloro

  125. Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT)

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), November 2021, De Gruyter

    Dr Emmanuel J Favaloro

  126. Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing

    Article • Journal of Thrombosis and Haemostasis, November 2021, Elsevier

    Dr Emmanuel J Favaloro

  127. Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More

    Article • Seminars in Thrombosis and Hemostasis, October 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  128. Editorial Compilation X

    Article • Seminars in Thrombosis and Hemostasis, October 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  129. New STH (2020) Impact Factor, Most Highly Cited Papers, and Other Journal Metrics

    Article • Seminars in Thrombosis and Hemostasis, October 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  130. The Intriguing Relationships of von Willebrand Factor, ADAMTS13 and Cardiac Disease

    Article • Journal of Cardiovascular Development and Disease, September 2021, MDPI AG

    Dr Emmanuel J Favaloro

  131. Why is Misdiagnosis of von Willebrand Disease Still Prevalent and How Can We Overcome It? A Focus on Clinical Considerations and Recommendations

    Article • Journal of Blood Medicine, August 2021, Taylor & Francis

    Dr Emmanuel J Favaloro

  132. Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)

    Article • Journal of Thrombosis and Thrombolysis, July 2021, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  133. COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check?

    Article • Seminars in Thrombosis and Hemostasis, June 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  134. Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature

    Article • Seminars in Thrombosis and Hemostasis, June 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  135. Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2021, De Gruyter

    Dr Emmanuel J Favaloro

  136. A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2021, De Gruyter

    Dr Emmanuel J Favaloro

  137. Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19): Part II

    Article • Seminars in Thrombosis and Hemostasis, June 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  138. Variability in D-dimer reporting revisited

    Article • Pathology, June 2021, Elsevier

    Dr Emmanuel J Favaloro

  139. Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond

    Article • American Journal of Hematology, May 2021, Wiley

    Dr Emmanuel J Favaloro

  140. The complicated relationships of heparin‐induced thrombocytopenia and platelet factor 4 antibodies with COVID‐19

    Article • International Journal of Laboratory Hematology, May 2021, Wiley

    Dr Emmanuel J Favaloro

  141. Verification of the ACL Top 50 Family (350, 550, and 750) for Harmonization of Routine Coagulation Assays in a Large Network of 60 Laboratories

    Article • American Journal of Clinical Pathology, April 2021, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  142. Mean Platelet Volume Predicts Severe COVID-19 Illness

    Article • Seminars in Thrombosis and Hemostasis, April 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  143. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis

    Article • Seminars in Thrombosis and Hemostasis, April 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  144. 2021 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, April 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  145. Effect of sample heat inactivation on test levels of HIT-IgG(PF4-H) detected by the ACL AcuStar

    Article • Thrombosis Research, April 2021, Elsevier

    Dr Emmanuel J Favaloro

  146. 2020 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, April 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  147. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment

    Article • Expert Review of Hematology, March 2021, Taylor & Francis

    Dr Emmanuel J Favaloro

  148. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

    Article • Thrombosis and Haemostasis, March 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  149. A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity

    Article • Journal of Thrombosis and Haemostasis, February 2021, Elsevier

    Dr Emmanuel J Favaloro

  150. A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia

    Article • Pathology, February 2021, Elsevier

    Dr Emmanuel J Favaloro

  151. Editorial Compilation IX

    Article • Seminars in Thrombosis and Hemostasis, February 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  152. Welcome to Seminars in Thrombosis & Hemostasis 2021—New (2019) Impact Factor and Most Highly Cited Papers

    Article • Seminars in Thrombosis and Hemostasis, February 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  153. Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study

    Article • Seminars in Thrombosis and Hemostasis, January 2021, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  154. 2B or not 2B? A diagnosis of von Willebrand disease a lifetime of 86 years in the making

    Article • Blood Coagulation & Fibrinolysis, January 2021, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  155. Coronavirus Disease 2019–Associated Coagulopathy

    Article • Mayo Clinic Proceedings, January 2021, Elsevier

    Dr Emmanuel J Favaloro

  156. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID‐19: Evidence of SARS‐CoV‐2 induced secondary thrombotic microangiopathy

    Article • International Journal of Laboratory Hematology, December 2020, Wiley

    Dr Emmanuel J Favaloro

  157. Sample stability for routine coagulation testing

    Article • Thrombosis Research, December 2020, Elsevier

    Dr Emmanuel J Favaloro

  158. D-dimer measurement in COVID-19: Silver bullet or clinical distraction?

    Article • Thrombosis Research, December 2020, Elsevier

    Dr Emmanuel J Favaloro

  159. How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types

    Article • Haemophilia, November 2020, Wiley

    Dr Emmanuel J Favaloro

  160. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis

    Article • Journal of Thrombosis and Haemostasis, November 2020, Elsevier

    Dr Emmanuel J Favaloro

  161. Oral anticoagulation therapy: an update on usage, costs and associated risks

    Article • Pathology, October 2020, Elsevier

    Dr Emmanuel J Favaloro

  162. Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part I

    Article • Seminars in Thrombosis and Hemostasis, October 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  163. Plasma vs serum as test sample for the chemiluminescent AcuStar HemosIL HIT‐IgG(PF4‐H) assay

    Article • International Journal of Laboratory Hematology, September 2020, Wiley

    Dr Emmanuel J Favaloro

  164. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR)

    Article • International Journal of Laboratory Hematology, September 2020, Wiley

    Dr Emmanuel J Favaloro

  165. Periodontal Disease and Venous Thromboembolism

    Article • Seminars in Thrombosis and Hemostasis, September 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  166. Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19)

    Article • Seminars in Thrombosis and Hemostasis, September 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  167. Hematology Laboratory Abnormalities in Patients with Coronavirus Disease 2019 (COVID-19)

    Article • Seminars in Thrombosis and Hemostasis, September 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  168. “Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendation from the women's SSC of the ISTH”: Response to comment from Kitchen et al

    Article • Journal of Thrombosis and Haemostasis, September 2020, Elsevier

    Dr Emmanuel J Favaloro

  169. Anticoagulant and antithrombotic therapy: globally applied according to local geographical selection criteria

    Article • Annals of Blood, September 2020, AME Publishing Company

    Dr Emmanuel J Favaloro

  170. Novel approaches to ensuring quality in laboratory diagnostics and external quality assessment

    Article • Annals of Blood, September 2020, AME Publishing Company

    Dr Emmanuel J Favaloro

  171. Statins and other drugs: Facing COVID-19 as a vascular disease

    Article • Pharmacological Research, September 2020, Elsevier

    Dr Emmanuel J Favaloro

  172. The need for accurate D‐dimer reporting in COVID‐19: Communication from the ISTH SSC on fibrinolysis

    Article • Journal of Thrombosis and Haemostasis, September 2020, Elsevier

    Dr Emmanuel J Favaloro

  173. Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies

    Article • Research and Practice in Thrombosis and Haemostasis, August 2020, Elsevier

    Dr Emmanuel J Favaloro

  174. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

    Article • Clinica Chimica Acta, August 2020, Elsevier

    Dr Emmanuel J Favaloro

  175. Periodontitis, coronary heart disease and myocardial infarction: treat one, benefit all

    Article • Blood Coagulation & Fibrinolysis, July 2020, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  176. Navigating the Myriad of von Willebrand Factor Assays

    Article • Hämostaseologie, June 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  177. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

    Article • Journal of the American College of Cardiology, June 2020, Elsevier

    Dr Emmanuel J Favaloro

  178. 2020 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, June 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  179. Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

    Article • European Journal of Internal Medicine, June 2020, Elsevier

    Dr Emmanuel J Favaloro

  180. Editorial Compilation VIII

    Article • Seminars in Thrombosis and Hemostasis, June 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  181. Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?

    Article • Blood Coagulation & Fibrinolysis, June 2020, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  182. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays

    Article • International Journal of Laboratory Hematology, June 2020, Wiley

    Dr Emmanuel J Favaloro

  183. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

    Article • Thrombosis and Haemostasis, May 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  184. Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2020, De Gruyter

    Dr Emmanuel J Favaloro

  185. COVID-19: progression of disease and intravascular coagulation – present status and future perspectives

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2020, De Gruyter

    Dr Emmanuel J Favaloro

  186. Mean platelet volume in arterial and venous thrombotic disorders

    Article • Journal of Laboratory Medicine, April 2020, De Gruyter

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  187. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

    Article • Thrombosis and Haemostasis, April 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  188. Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring

    Article • Seminars in Thrombosis and Hemostasis, April 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  189. Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making

    Article • Thrombosis Research, April 2020, Elsevier

    Dr Emmanuel J Favaloro

  190. Mixing studies for lupus anticoagulant: mostly yes, sometimes no

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), March 2020, De Gruyter

    Dr Emmanuel J Favaloro

  191. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies

    Article • Haemophilia, March 2020, Wiley

    Dr Emmanuel J Favaloro

  192. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), March 2020, De Gruyter

    Dr Emmanuel J Favaloro

  193. Impact of water temperature on reconstitution of quality controls for routine hemostasis testing

    Article • Diagnosis, February 2020, De Gruyter

    Dr Emmanuel J Favaloro

  194. Welcome to Seminars in Thrombosis and Hemostasis 2020—New (2018) Impact Factor and Most Highly Cited Papers

    Article • Seminars in Thrombosis and Hemostasis, February 2020, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  195. Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study

    Article • Research and Practice in Thrombosis and Haemostasis, February 2020, Elsevier

    Dr Emmanuel J Favaloro

  196. Unfractionated heparin monitoring with activated partial thromboplastin time

    Article • Pathology, February 2020, Elsevier

    Dr Emmanuel J Favaloro

  197. Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects

    Article • Haemophilia, January 2020, Wiley

    Dr Emmanuel J Favaloro

  198. Understanding the extent of the diagnostic potential of coagulation factors

    Article • Expert Review of Molecular Diagnostics, January 2020, Taylor & Francis

    Dr Emmanuel J Favaloro

  199. An Update on Biological and Clinical Associations between E-Cigarettes and Myocardial Infarction

    Article • Seminars in Thrombosis and Hemostasis, December 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  200. Direct Oral Anticoagulants for Disseminated Intravascular Coagulation: An Alliterative Wordplay or Potentially Valuable Therapeutic Interventions?

    Article • Seminars in Thrombosis and Hemostasis, December 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  201. Coagulation studies: achieving the right mix in a large laboratory network

    Article • Pathology, December 2019, Elsevier

    Dr Emmanuel J Favaloro

  202. The Pointy End of Point-of-Care Testing for Direct Oral Anticoagulants

    Article • Thrombosis and Haemostasis, November 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  203. Coagulation mixing studies: Utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests

    Article • American Journal of Hematology, November 2019, Wiley

    Dr Emmanuel J Favaloro

  204. International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting

    Article • Seminars in Thrombosis and Hemostasis, October 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  205. Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction

    Article • Seminars in Thrombosis and Hemostasis, October 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  206. Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics

    Article • Seminars in Thrombosis and Hemostasis, September 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  207. Platelet Transfusion Thresholds: How Low Can We Go in Respect to Platelet Counting?

    Article • Seminars in Thrombosis and Hemostasis, September 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  208. Semi‐automated von Willebrand factor multimer assay for von Willebrand disease: Further validation, benefits and limitations

    Article • International Journal of Laboratory Hematology, September 2019, Wiley

    Dr Emmanuel J Favaloro

  209. A diagnosis of von Willebrand disease despite normal test results for factor VIII and von Willebrand factor antigen and activity

    Article • American Journal of Hematology, August 2019, Wiley

    Dr Emmanuel J Favaloro

  210. The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA)

    Article • American Journal of Hematology, August 2019, Wiley

    Dr Emmanuel J Favaloro

  211. The Model List of Essential In Vitro Diagnostics: nuisance or opportunity?

    Article • Diagnosis, August 2019, De Gruyter

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  212. Understanding the “philosophy” of laboratory hemostasis

    Article • Diagnosis, August 2019, De Gruyter

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  213. Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene “Mutation” (G20210A)

    Article • Seminars in Thrombosis and Hemostasis, August 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  214. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa

    Article • Thrombosis Research, August 2019, Elsevier

    Dr Emmanuel J Favaloro

  215. Development and implementation of an expert rule set for automated reflex testing and validation of routine coagulation tests in a large pathology network

    Article • International Journal of Laboratory Hematology, July 2019, Wiley

    Dr Emmanuel J Favaloro

  216. Editorial Compilation VII

    Article • Seminars in Thrombosis and Hemostasis, July 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  217. Current and Emerging Direct Oral Anticoagulants: State-of-the-Art

    Article • Seminars in Thrombosis and Hemostasis, June 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  218. Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New ZealandHITWriting Group

    Article • The Medical Journal of Australia, June 2019, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

    Marie-Christine Morel-Kopp, Dr Emmanuel J Favaloro

  219. Statins for Preventing Venous Thrombosis: For or Against?

    Article • Seminars in Thrombosis and Hemostasis, May 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  220. Vascular Disease and Dementia: Lipoprotein(a) as a Neglected Link

    Article • Seminars in Thrombosis and Hemostasis, May 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  221. Impact of low volume citrate tubes on results of first‐line hemostasis testing

    Article • International Journal of Laboratory Hematology, April 2019, Wiley

    Dr Emmanuel J Favaloro

  222. Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), April 2019, De Gruyter

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  223. 2019 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, April 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  224. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives

    Article • Pathology, April 2019, Elsevier

    Dr Emmanuel J Favaloro

  225. Thrombin generation in different commercial sodium citrate blood tubes

    Article • Journal of Medical Biochemistry, March 2019, Centre for Evaluation in Education and Science (CEON/CEES)

    Dr Emmanuel J Favaloro

  226. Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing

    Article • Seminars in Thrombosis and Hemostasis, March 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  227. 2018 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, March 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  228. To Maintain or Cease Non–Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations

    Article • Seminars in Thrombosis and Hemostasis, February 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  229. Analytical Assessment of the New Roche Cobas t 711 Fully Automated Coagulation Analyzer

    Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

    Dr Davide Giavarina, Dr Emmanuel J Favaloro

  230. Editorial Compilation VI

    Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  231. Welcome to Seminars in Thrombosis and Hemostasis 2019–New (2017) Impact Factor and Most Highly Cited Papers

    Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  232. Commentary: Controversies in Thrombosis and Hemostasis Part 2–Does Sticky Platelet Syndrome Exist?

    Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  233. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors

    Article • Seminars in Thrombosis and Hemostasis, January 2019, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  234. Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A

    Article • January 2019, Elsevier

    Dr Emmanuel J Favaloro

  235. Lessons learnt from local real‐life experience with idarucizumab for the reversal of dabigatran

    Article • Internal Medicine Journal, January 2019, Wiley

    Dr Emmanuel J Favaloro

  236. Analytical performance of the new D‐dimer and antithrombin assay on Roche cobas t 711 analyzer

    Article • International Journal of Laboratory Hematology, December 2018, Wiley

    Dr Emmanuel J Favaloro

  237. Dark chocolate modulates platelet function with a mechanism mediated by flavan-3-ol metabolites

    Article • Medicine, December 2018, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  238. Danger of false negative (exclusion) or false positive (diagnosis) for ‘congenital thrombophilia’ in the age of anticoagulants

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), November 2018, De Gruyter

    Dr Emmanuel J Favaloro

  239. Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview

    Article • Seminars in Thrombosis and Hemostasis, October 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  240. Anticoagulation at the extremes of body weight: choices and dosing

    Article • Expert Review of Hematology, September 2018, Taylor & Francis

    Dr Jennifer Curnow, Dr Emmanuel J Favaloro

  241. Rare forms of von Willebrand disease

    Article • Annals of Translational Medicine, September 2018, AME Publishing Company

    Dr Emmanuel J Favaloro

  242. e-thrombosis: epidemiology, physiopathology and rationale for preventing computer-related thrombosis

    Article • Annals of Translational Medicine, September 2018, AME Publishing Company

    Dr Emmanuel J Favaloro

  243. How to Generate a More Accurate Laboratory-Based International Normalized Ratio: Solutions to Obtaining or Verifying the Mean Normal Prothrombin Time and International Sensitivity Index

    Article • Seminars in Thrombosis and Hemostasis, August 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  244. Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes

    Article • Seminars in Thrombosis and Hemostasis, August 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  245. Postanalytical considerations that may improve the diagnosis or exclusion of haemophilia and von Willebrand disease

    Article • Haemophilia, July 2018, Wiley

    Dr Emmanuel J Favaloro

  246. Laboratory hemostasis: from biology to the bench

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2018, De Gruyter

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  247. 45 years of Seminars in Thrombosis and Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, June 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  248. Myocardial Infarction, Unstable Angina, and White Thrombi: Time to Move Forward?

    Article • Seminars in Thrombosis and Hemostasis, June 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  249. Sudden Cardiac and Noncardiac Death in Sports: Epidemiology, Causes, Pathogenesis, and Prevention

    Article • Seminars in Thrombosis and Hemostasis, June 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  250. A 2018 Update on the Editorial and Publication Policy of Seminars in Thrombosis and Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, June 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  251. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study

    Article • Thrombosis Research, June 2018, Elsevier

    Dr Emmanuel J Favaloro

  252. HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia

    Article • Pathology, June 2018, Elsevier

    Dr Emmanuel J Favaloro

  253. Mathematical rounding as a post-analytical issue in pathology reporting: generation of bias in INR resulting

    Article • Pathology, June 2018, Elsevier

    Dr Emmanuel J Favaloro

  254. An update on quality control for the PFA-100/PFA-200

    Article • Platelets, May 2018, Taylor & Francis

    Dr Emmanuel J Favaloro

  255. Car Travel-Related Thrombosis: Fact or Fiction?

    Article • Seminars in Thrombosis and Hemostasis, May 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  256. Not as sweet as honey: A rare case of an apparent factor V “inhibitor” in association with bee sting anaphylaxis

    Article • American Journal of Hematology, May 2018, Wiley

    Dr Emmanuel J Favaloro

  257. Recent initiatives in harmonization of hemostasis practice

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2018, De Gruyter

    Dr Emmanuel J Favaloro

  258. On the complexity of hemostasis and the need for harmonization of test practice

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2018, De Gruyter

    Dr Emmanuel J Favaloro

  259. Towards harmonization of external quality assessment/proficiency testing in hemostasis

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), April 2018, De Gruyter

    Dr Emmanuel J Favaloro

  260. Management of pregnancy complications in type 2N von Willebrand disease associated to a novel mutation

    Article • Haemophilia, April 2018, Wiley

    Dr Emmanuel J Favaloro

  261. 2018 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, April 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  262. Editorial Compilation V

    Article • Seminars in Thrombosis and Hemostasis, April 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  263. 2017 Eberhard F. Mammen Award Announcements: Part II–Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, February 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  264. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

    Article • Thrombosis and Haemostasis, February 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  265. Welcome to Seminars in Thrombosis & Hemostasis 2018. New (2016) Impact Factor and Most Highly Cited Papers

    Article • Seminars in Thrombosis and Hemostasis, February 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  266. Assessment of Plasma Sample Quality on Siemens Atellica COAG 360 System

    Article • Seminars in Thrombosis and Hemostasis, January 2018, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  267. von Willebrand Disease

    Article • January 2018, Springer Science + Business Media

    Shadi Tabibin , Dr Emmanuel J Favaloro

  268. von Willebrand Disease

    Article • January 2018, Elsevier

    Dr Emmanuel J Favaloro

  269. Lack of grading agreement among international hemostasis external quality assessment programs

    Article • Blood Coagulation & Fibrinolysis, January 2018, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  270. Preanalytical issues that may cause misdiagnosis in haemophilia and von Willebrand disease

    Article • Haemophilia, December 2017, Wiley

    Dr Emmanuel J Favaloro

  271. Commentary: Controversies in Thrombosis and Hemostasis Part 1—Hematidrosis: “Blood, Sweat and Fears” or A “Pigment of Fertile Imaginations?”

    Article • Seminars in Thrombosis and Hemostasis, December 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  272. Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?

    Article • American Journal of Hematology, December 2017, Wiley

    Dr Emmanuel J Favaloro

  273. Time dependent reduction in platelet aggregation using the multiplate analyser and hirudin blood due to platelet clumping

    Article • Platelets, December 2017, Taylor & Francis

    Dr Emmanuel J Favaloro

  274. Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B

    Article • Expert Opinion on Biological Therapy, November 2017, Taylor & Francis

    Dr Emmanuel J Favaloro

  275. The increasing maturity of the von Willebrand factor collagen binding in von Willebrand disease diagnosis

    Article • Haemophilia, November 2017, Wiley

    Dr Emmanuel J Favaloro

  276. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing

    Article • Pathology, October 2017, Elsevier

    Dr Emmanuel J Favaloro

  277. Venous and Arterial Thromboses: Two Sides of the Same Coin?

    Article • Seminars in Thrombosis and Hemostasis, September 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  278. Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges

    Article • Current Drug Metabolism, September 2017, Bentham Science Publishers

    Dr Emmanuel J Favaloro

  279. Gender related issues in thrombosis and hemostasis

    Article • Expert Review of Hematology, August 2017, Taylor & Francis

    Dr Emmanuel J Favaloro

  280. Editorial Compilation IV

    Article • Seminars in Thrombosis and Hemostasis, August 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  281. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends

    Article • Annals of Translational Medicine, August 2017, AME Publishing Company

    Dr Emmanuel J Favaloro

  282. Potential misdiagnosis of von Willebrand disease and haemophilia caused by ineffective mixing of thawed plasma

    Article • Haemophilia, July 2017, Wiley

    Dr Gabriel Lima-Oliveira, Dr Emmanuel J Favaloro

  283. Managing the patient identification crisis in healthcare and laboratory medicine

    Article • Clinical Biochemistry, July 2017, Elsevier

    Dr Emmanuel J Favaloro

  284. Therapeutic monitoring of unfractionated heparin – trials and tribulations

    Article • Expert Review of Hematology, June 2017, Taylor & Francis

    Dr Emmanuel J Favaloro

  285. Novel (Oral) Anticoagulant Challenges in Surgery

    Article • Seminars in Thrombosis and Hemostasis, June 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  286. Serum Concentration of Growth Differentiation Factor-15 Is Independently Associated with Global Platelet Function and Higher Fibrinogen Values in Adult Healthy Subjects

    Article • Seminars in Thrombosis and Hemostasis, June 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  287. Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update

    Article • Pathology, June 2017, Elsevier

    Dr Emmanuel J Favaloro

  288. 2017 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, May 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  289. Evaluation of a new commercial von Willebrand factor multimer assay

    Article • Haemophilia, May 2017, Wiley

    Dr Emmanuel J Favaloro

  290. 2B or not 2B? A prothrombotic tendency masquerading as a bleeding disorder

    Article • American Journal of Hematology, May 2017, Wiley

    Dr Emmanuel J Favaloro

  291. Translational aspects of developmental hemostasis: infants and children are not miniature adults and even adults may be different

    Article • Annals of Translational Medicine, May 2017, AME Publishing Company

    Dr Emmanuel J Favaloro

  292. Impact of experimental hypercalcemia on routine haemostasis testing

    Article • PLoS ONE, March 2017, PLOS

    Dr Emmanuel J Favaloro

  293. 2016 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, March 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  294. The Intriguing Link between the Intestinal Microbiota and Cardiovascular Disease

    Article • Seminars in Thrombosis and Hemostasis, March 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  295. Platelet function testing in pediatric patients

    Article • Expert Review of Hematology, March 2017, Taylor & Francis

    Dr Emmanuel J Favaloro

  296. Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?

    Article • Annals of Translational Medicine, March 2017, AME Publishing Company

    Dr Emmanuel J Favaloro

  297. Welcome to Seminars in Thrombosis & Hemostasis 2017 — New (2015) Impact Factor and Most Highly Cited Papers

    Article • Seminars in Thrombosis and Hemostasis, February 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  298. Editorial Compilation III

    Article • Seminars in Thrombosis and Hemostasis, February 2017, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  299. Critical laboratory values in hemostasis: toward consensus

    Article • Annals of Medicine, February 2017, Taylor & Francis

    Dr Emmanuel J Favaloro

  300. Clinical utility of closure times using the platelet function analyzer‐100/200

    Article • American Journal of Hematology, February 2017, Wiley

    Dr Emmanuel J Favaloro

  301. Explaining and reducing the variation in inter-laboratory reported values for International Normalised Ratio

    Article • Thrombosis Research, February 2017, Elsevier

    Dr Emmanuel J Favaloro

  302. Exploring the iceberg of inappropriateness in hemostasis testing

    Article • Diagnosis, January 2017, De Gruyter

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  303. Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  304. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD)

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  305. Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo)

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  306. Laboratory Testing for Activated Protein C Resistance (APCR)

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  307. Laboratory Testing for Von Willebrand Factor Multimers

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  308. Laboratory Testing for von Willebrand Factor Antigen (VWF:Ag)

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  309. Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB)

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  310. Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb)

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  311. Laboratory Testing Protocols for Heparin-Induced Thrombocytopenia (HIT) Testing

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  312. Optimizing the Verification of Mean Normal Prothrombin Time (MNPT) and International Sensitivity Index (ISI) for Accurate Conversion of Prothrombin Time (PT) to International Normalized Ratio (INR)

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  313. Overview of Hemostasis and Thrombosis and Contribution of Laboratory Testing to Diagnosis and Management of Hemostasis and Thrombosis Disorders

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  314. Platelet Function Analyzed by Light Transmission Aggregometry

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  315. Preanalytical Issues in Hemostasis and Thrombosis Testing

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  316. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  317. Laboratory monitoring of direct oral anticoagulants (DOACs)—The perfect storm?

    Article • Annals of Translational Medicine, January 2017, AME Publishing Company

    Dr Emmanuel J Favaloro

  318. D-Dimer Testing: Laboratory Aspects and Current Issues

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  319. Post-analytical Issues in Hemostasis and Thrombosis Testing

    Article • January 2017, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  320. Critical pre-examination variables in the hemostasis laboratory and their quality indicators

    Article • Clinical Biochemistry, December 2016, Elsevier

    Dr Emmanuel J Favaloro

  321. Mixing of thawed coagulation samples prior to testing: Is any technique better than another?

    Article • Clinical Biochemistry, December 2016, Elsevier

    Dr Emmanuel J Favaloro

  322. Troubleshooting an isolate prolongation of activated partial thromboplastin time in a patient with acute myocardial infarction—a paradigmatic case report

    Article • Annals of Translational Medicine, November 2016, AME Publishing Company

    Dr Emmanuel J Favaloro

  323. Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease

    Article • American Journal of Hematology, October 2016, Wiley

    Dr Emmanuel J Favaloro

  324. Giuseppe (Joseph) Favaloro (1922–2016)

    Article • Seminars in Thrombosis and Hemostasis, September 2016, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  325. Editorial Compilation—II

    Article • Seminars in Thrombosis and Hemostasis, September 2016, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  326. Monitoring Therapy during Treatment of von Willebrand Disease

    Article • Seminars in Thrombosis and Hemostasis, July 2016, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  327. Laboratory tests used to help diagnose von Willebrand disease: an update

    Article • Pathology, June 2016, Elsevier

    Dr Emmanuel J Favaloro

  328. Andexanet: Effectively Reversing Anticoagulation

    Article • Trends in Pharmacological Sciences, June 2016, Elsevier

    Dr Emmanuel J Favaloro

  329. Characterizing the Mechanistic Pathways of the Instant Blood-Mediated Inflammatory Reaction in Xenogeneic Neonatal Islet Cell Transplantation

    Article • Transplantation Direct, June 2016, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  330. Type 2M and Type 2A von Willebrand Disease: Similar but Different

    Article • Seminars in Thrombosis and Hemostasis, May 2016, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  331. 2016 Eberhard F. Mammen Award Announcements: Part I — Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, May 2016, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  332. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease

    Article • Thrombosis Research, May 2016, Elsevier

    Dr Emmanuel J Favaloro

  333. Diagnostics of Inherited Bleeding Disorders of Secondary Hemostasis: An Easy Guide for Routine Clinical Laboratories

    Article • Seminars in Thrombosis and Hemostasis, April 2016, Thieme Publishing Group

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  334. Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data

    Article • Drugs in Context, April 2016, BioExcel

    Dr Emmanuel J Favaloro

  335. Type 2M von Willebrand disease - more often misidentified than correctly identified

    Article • Haemophilia, March 2016, Wiley

    Dr Emmanuel J Favaloro

  336. Why Do Patients Bleed?

    Article • The Surgery Journal, February 2016, Thieme Publishing Group

    Dr Jennifer Curnow, Dr Emmanuel J Favaloro

  337. Editorial Compilation I

    Article • Seminars in Thrombosis and Hemostasis, February 2016, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  338. Welcome to Seminars in Thrombosis & Hemostasis 2016: New (2014) Impact Factor and Most Highly Cited Articles

    Article • Seminars in Thrombosis and Hemostasis, February 2016, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  339. Treatment of von Willebrand Disease

    Article • Seminars in Thrombosis and Hemostasis, February 2016, Thieme Publishing Group

    Dr Jennifer Curnow, Dr Emmanuel J Favaloro

  340. Harmonizing the International Normalized Ratio (INR)

    Article • American Journal of Clinical Pathology, January 2016, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  341. Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH

    Article • Journal of Thrombosis and Haemostasis, January 2016, Wiley

    Dr Emmanuel J Favaloro

  342. Hereditary Thrombophilias: Pathophysiology, Timing of Testing and Familial Testing

    Article • January 2016, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  343. Harmonisation of D-dimer — A call for action

    Article • Thrombosis Research, January 2016, Elsevier

    Dr Emmanuel J Favaloro

  344. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

    Article • Pathology, January 2016, Elsevier

    Dr Emmanuel J Favaloro

  345. Allergy and Venous Thromboembolism: A Casual or Causative Association

    Article • Seminars in Thrombosis and Hemostasis, December 2015, Thieme Publishing Group

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  346. 2015 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, November 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  347. 2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, October 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  348. Influence of posture on routine hemostasis testing

    Article • Blood Coagulation & Fibrinolysis, September 2015, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  349. “Bleeding in the jungle”

    Article • American Journal of Hematology, August 2015, Wiley

    Dr Emmanuel J Favaloro

  350. Toward improved diagnosis of HIT

    Article • Blood, July 2015, American Society of Hematology

    Dr Emmanuel J Favaloro

  351. Recent advances in laboratory-aided diagnosis of von Willebrand disease

    Article • Expert Opinion on Orphan Drugs, July 2015, Informa Healthcare

    Dr Emmanuel J Favaloro

  352. Effect of contaminant 0.9% saline on tests of haemostasis

    Article • Anaesthesia, July 2015, Wiley

    Dr Emmanuel J Favaloro

  353. Commentary

    Article • Clinical Chemistry, July 2015, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  354. Determining the stability of complete blood count parameters in stored blood samples using the SYSMEX XE-5000 automated haematology analyser

    Article • International Journal of Laboratory Hematology, June 2015, Wiley

    Dr Emmanuel J Favaloro

  355. Hot Topics VII

    Article • Seminars in Thrombosis and Hemostasis, June 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  356. Laboratory monitoring of warfarin in the era of direct oral anticoagulants

    Article • The Lancet Haematology, June 2015, Elsevier

    Dr Emmanuel J Favaloro

  357. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

    Article • Pathology, June 2015, Elsevier

    Dr Emmanuel J Favaloro

  358. The Platelet Function Analyser (PFA)-100 and von Willebrand disease: a story well over 16 years in the making

    Article • Haemophilia, May 2015, Wiley

    Dr Emmanuel J Favaloro

  359. Pearls and pitfalls in factor inhibitor assays

    Article • International Journal of Laboratory Hematology, May 2015, Wiley

    Dr Emmanuel J Favaloro

  360. Detection of mild inherited disorders of blood coagulation: current options and personal recommendations

    Article • Expert Review of Hematology, April 2015, Taylor & Francis

    Dr Emmanuel J Favaloro

  361. Newer Hemostatic Agents

    Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  362. Quality in Hemostasis and Thrombosis — Part IV

    Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  363. Diagnostics in Venous Thromboembolism: From Origin to Future Prospects

    Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  364. International Normalized Ratio Monitoring of Vitamin K Antagonist Therapy: Comparative Performance of Point-of-Care and Laboratory-Derived Testing

    Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  365. International Survey on D-Dimer Test Reporting: A Call for Standardization

    Article • Seminars in Thrombosis and Hemostasis, April 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  366. Anticoagulant Therapy: Present and Future

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  367. The Changing Face of Hemostasis Testing in Modern Laboratories: Consolidation, Automation, and Beyond

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  368. Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  369. Next Generation Antithrombotic Therapy: Focus on Antisense Therapy against Coagulation Factor XI

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Job Harenberg, Dr Emmanuel J Favaloro

  370. Welcome to Seminars in Thrombosis & Hemostasis 2015: New (2013) Impact Factor and Most Highly Cited Articles

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  371. Reflections on the next generation of hemostasis instrumentation. A glimpse into the future?

    Article • LaboratoriumsMedizin, January 2015, De Gruyter

    Giuseppe Lippi, Dr Emmanuel J Favaloro

  372. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2015, De Gruyter

    Dr Emmanuel J Favaloro

  373. The new and the old of heparin-induced thrombocytopenia

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2015, De Gruyter

    Dr Emmanuel J Favaloro

  374. The effect of hyperglycaemia on haemostasis testing - a volunteer study

    Article • Anaesthesia, December 2014, Wiley

    Dr Emmanuel J Favaloro

  375. Towards improved diagnosis of von Willebrand disease: Comparative evaluations of several automated von Willebrand factor antigen and activity assays

    Article • Thrombosis Research, December 2014, Elsevier

    Dr Emmanuel J Favaloro

  376. Evaluating the interaction of von Willebrand factor and ADAMTS13 - and perhaps also beyond ADAMTS13

    Article • Thrombosis Research, December 2014, Elsevier

    Dr Emmanuel J Favaloro

  377. Urgent monitoring of dabigatran plasma levels: sometimes less is more

    Article • Polish Archives of Internal Medicine, November 2014, Towarzystwo Internistow Polskich/Polish Society of Internal Medicine

    Dr Emmanuel J Favaloro

  378. Dedication

    Article • Seminars in Thrombosis and Hemostasis, November 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  379. Articles from Seminars in Thrombosis & Hemostasis (STH) Archives: Part II

    Article • Seminars in Thrombosis and Hemostasis, November 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  380. A Short History of Thrombosis and Hemostasis: Part II (40th Year Celebratory Issue)

    Article • Seminars in Thrombosis and Hemostasis, November 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  381. Hot Topics VI

    Article • Seminars in Thrombosis and Hemostasis, October 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  382. 2014 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

    Article • Seminars in Thrombosis and Hemostasis, October 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  383. Dangers in the Practice of Defensive Medicine in Hemostasis Testing for Investigation of Bleeding or Thrombosis: Part I—Routine Coagulation Testing

    Article • Seminars in Thrombosis and Hemostasis, October 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  384. Sodium citrate blood contamination by K2-ethylenediaminetetraacetic acid (EDTA): impact on routine coagulation testing

    Article • International Journal of Laboratory Hematology, October 2014, Wiley

    Dr Gabriel Lima-Oliveira, Dr Emmanuel J Favaloro

  385. Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines

    Article • Pathology, October 2014, Elsevier

    Dr Emmanuel J Favaloro

  386. Thrombophilia testing in patients taking direct oral anticoagulants. Handle with care

    Article • Diagnosis, September 2014, De Gruyter

    Dr Emmanuel J Favaloro

  387. A Review of the Value of D-dimer Testing for Prediction of Recurrent Venous Thromboembolism with Increasing Age

    Article • Seminars in Thrombosis and Hemostasis, August 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  388. Aging Hemostasis: Changes to Laboratory Markers of Hemostasis As We Age—A Narrative Review

    Article • Seminars in Thrombosis and Hemostasis, August 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  389. Evaluating errors in the laboratory identification of von Willebrand disease in the real world

    Article • Thrombosis Research, August 2014, Elsevier

    Dr Emmanuel J Favaloro

  390. Comparative sensitivity of commercially available aPTT reagents to mulga snake (Pseudechis australis) venom

    Article • Pathology, August 2014, Elsevier

    Dr Emmanuel J Favaloro

  391. A Short History of Thrombosis and Hemostasis: Part I (40th Year Celebratory Issue)

    Article • Seminars in Thrombosis and Hemostasis, July 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  392. Articles from Seminars in Thrombosis & Hemostasis (STH) Archives

    Article • Seminars in Thrombosis and Hemostasis, July 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  393. Diagnosing von Willebrand Disease: A Short History of Laboratory Milestones and Innovations, Plus Current Status, Challenges, and Solutions

    Article • Seminars in Thrombosis and Hemostasis, June 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  394. Combined Administration of Antibiotics and Direct Oral Anticoagulants: A Renewed Indication for Laboratory Monitoring?

    Article • Seminars in Thrombosis and Hemostasis, June 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  395. Response to “Comment on E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism”

    Article • Seminars in Thrombosis and Hemostasis, May 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  396. 2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

    Article • Seminars in Thrombosis and Hemostasis, May 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  397. Laboratory testing for factor inhibitors

    Article • Haemophilia, April 2014, Wiley

    Dr Emmanuel J Favaloro

  398. von Willebrand disease and platelet disorders

    Article • Haemophilia, April 2014, Wiley

    Dr Emmanuel J Favaloro

  399. Interference from heterophilic antibodies in D-dimer assessment. A case report

    Article • Blood Coagulation & Fibrinolysis, April 2014, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  400. Influence of centrifuge brake on residual platelet count and routine coagulation tests in citrated plasma

    Article • Blood Coagulation & Fibrinolysis, April 2014, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  401. Artefactual “in-vitro coagulopathy” in a patient with non-Hodgkin lymphoma and lower gastrointestinal bleeding

    Article • The Medical Journal of Australia, March 2014, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

    Dr Emmanuel J Favaloro

  402. Quality in Hemostasis and Thrombosis — Part III

    Article • Seminars in Thrombosis and Hemostasis, February 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  403. Standardization and Harmonization of Antiphospholipid Antibody Assays

    Article • Seminars in Thrombosis and Hemostasis, February 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  404. External Quality Assessment/Proficiency Testing and Internal Quality Control for the PFA-100 and PFA-200: An Update

    Article • Seminars in Thrombosis and Hemostasis, February 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  405. A Tribute to Professor Jerry Koutts, MD (Syd), BS, FRACP, FRCPA (1944–2013)

    Article • Seminars in Thrombosis and Hemostasis, January 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  406. Welcome to Seminars in Thrombosis & Hemostasis 2014

    Article • Seminars in Thrombosis and Hemostasis, January 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  407. Hot Topics V

    Article • Seminars in Thrombosis and Hemostasis, January 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  408. Technological Advances in the Hemostasis Laboratory

    Article • Seminars in Thrombosis and Hemostasis, January 2014, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  409. The futility of thrombophilia testing

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2014, De Gruyter

    Dr Emmanuel J Favaloro

  410. von Willebrand Disease

    Article • January 2014, Elsevier

    Dr Emmanuel J Favaloro

  411. E-Cigarettes and Cardiovascular Risk: Beyond Science and Mysticism

    Article • Seminars in Thrombosis and Hemostasis, December 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  412. Problems and Solutions in Laboratory Testing for Hemophilia

    Article • Seminars in Thrombosis and Hemostasis, November 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  413. Editorial

    Article • Seminars in Thrombosis and Hemostasis, October 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  414. Technical Evaluation of the Novel Preanalytical Module on Instrumentation Laboratory ACL TOP: Advancing Automation in Hemostasis Testing

    Article • SLAS TECHNOLOGY, October 2013, Elsevier

    Dr Emmanuel J Favaloro

  415. Problems and Solutions in Laboratory Testing for Hemophilia

    Article • Seminars in Thrombosis and Hemostasis, September 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  416. Influence of Residual Platelet Count on Routine Coagulation, Factor VIII, and Factor IX Testing in Postfreeze-Thaw Samples

    Article • Seminars in Thrombosis and Hemostasis, September 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  417. Sample collection and platelet function testing

    Article • Blood Coagulation & Fibrinolysis, September 2013, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  418. Lupus anticoagulant testing – sometimes mixing is required

    Article • Blood Coagulation & Fibrinolysis, September 2013, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  419. Still more discussion on the journal impact factor

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), August 2013, De Gruyter

    Dr Emmanuel J Favaloro

  420. 2013 Eberhard F. Mammen Award Announcements

    Article • Seminars in Thrombosis and Hemostasis, August 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  421. Laboratory testing for the new oral anticoagulants: a review of current practice

    Article • Pathology, June 2013, Elsevier

    Dr Emmanuel J Favaloro

  422. Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors

    Article • Seminars in Thrombosis and Hemostasis, April 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  423. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants

    Article • International Journal of Laboratory Hematology, April 2013, Wiley

    Dr Emmanuel J Favaloro

  424. Quality in Hemostasis and Thrombosis, Part II

    Article • Seminars in Thrombosis and Hemostasis, March 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  425. Regulation in Hemostasis and Thrombosis: Part I—In Vitro Diagnostics

    Article • Seminars in Thrombosis and Hemostasis, March 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  426. Laboratory Evaluation of Von Willebrand Disease: Phenotypic Analysis

    Article • February 2013, Wiley

    Dr Emmanuel J Favaloro

  427. Causes of Errors in Medical Laboratories

    Article • February 2013, Wiley

    Dr Emmanuel J Favaloro

  428. External Quality Assessment of Factor VIII Inhibitor Assays

    Article • Seminars in Thrombosis and Hemostasis, February 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  429. Hot Topics IV

    Article • Seminars in Thrombosis and Hemostasis, February 2013, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  430. Trials and tribulations in lupus anticoagulant testing

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2013, De Gruyter

    Dr Emmanuel J Favaloro

  431. Article downloads and citations: Is there any relationship?

    Article • Clinica Chimica Acta, January 2013, Elsevier

    Dr Emmanuel J Favaloro

  432. Welcome to Seminars in Thrombosis & Hemostasis 2013

    Article • Seminars in Thrombosis and Hemostasis, December 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  433. Interference in Coagulation Testing: Focus on Spurious Hemolysis, Icterus, and Lipemia

    Article • Seminars in Thrombosis and Hemostasis, December 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  434. Time for a conceptual shift in assessment of internal quality control for whole blood or cell-based testing systems? An evaluation using platelet function and the PFA-100 as a case example

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), November 2012, De Gruyter

    Dr Emmanuel J Favaloro

  435. Establishment and characterization of a new and stable collagen‐binding assay for the assessment of von Willebrand factor activity

    Article • International Journal of Laboratory Hematology, October 2012, Wiley

    Dr Emmanuel J Favaloro

  436. Massive Posttraumatic Bleeding: Epidemiology, Causes, Clinical Features, and Therapeutic Management

    Article • Seminars in Thrombosis and Hemostasis, October 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  437. Novel and Emerging Therapies: Thrombus-Targeted Fibrinolysis

    Article • Seminars in Thrombosis and Hemostasis, October 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  438. Quality in Hemostasis and Thrombosis—Part I

    Article • Seminars in Thrombosis and Hemostasis, September 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  439. Discard tube for coagulation testing

    Article • Blood Coagulation & Fibrinolysis, September 2012, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  440. New developments in the diagnosis and treatment of von Willebrand disease

    Article • Clinical Investigation, August 2012, OMICS Publishing Group

    Dr Emmanuel J Favaloro

  441. ABO blood group, hypercoagulability, and cardiovascular and cancer risk

    Article • Critical Reviews in Clinical Laboratory Sciences, August 2012, Taylor & Francis

    Dr Emmanuel J Favaloro

  442. Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory Medicine

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), July 2012, De Gruyter

    Dr Emmanuel J Favaloro

  443. In Vitro and In Vivo Hemolysis

    Article • July 2012, De Gruyter

    Dr Emmanuel J Favaloro

  444. Thrombotic and Hemorrhagic Syndromes Associated with Autoimmunity and Infection

    Article • Seminars in Thrombosis and Hemostasis, July 2012, Thieme Publishing Group

    ANTONIO COPPOLA, Dr Emmanuel J Favaloro

  445. 2012 Eberhard F. Mammen Award Announcements

    Article • Seminars in Thrombosis and Hemostasis, July 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  446. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients: a rebuttal

    Article • Journal of Thrombosis and Haemostasis, July 2012, Elsevier

    Dr Emmanuel J Favaloro

  447. External Quality Assurance for Heparin Monitoring

    Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  448. Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia A

    Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

    ANTONIO COPPOLA, Dr Emmanuel J Favaloro

  449. Acquired Inhibitors of Coagulation Factors: Part II

    Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  450. Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis

    Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  451. Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders

    Article • Haemophilia, June 2012, Wiley

    Dr Emmanuel J Favaloro

  452. Quality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing

    Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  453. Quality Standards for Sample Collection in Coagulation Testing

    Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro, Dr Gabriel Lima-Oliveira

  454. Patient Safety and Quality in Laboratory and Hemostasis Testing: A Renewed Loop?

    Article • Seminars in Thrombosis and Hemostasis, June 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  455. Laboratory identification of factor inhibitors: an update

    Article • Pathology, June 2012, Elsevier

    Dr Emmanuel J Favaloro

  456. Differential sensitivity of von Willebrand factor (VWF) ‘activity’ assays to large and small VWF molecular weight forms: a cross‐laboratory study comparing ristocetin cofactor, collagen‐binding and mAb‐based assays

    Article • Journal of Thrombosis and Haemostasis, June 2012, Elsevier

    Dr Emmanuel J Favaloro

  457. Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT

    Article • Journal of Thrombosis and Thrombolysis, May 2012, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  458. Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy

    Article • Journal of Thrombosis and Thrombolysis, May 2012, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  459. The Antiphospholipid Syndrome: Diagnosis, Pathogenesis, Laboratory Testing, and Management

    Article • Seminars in Thrombosis and Hemostasis, May 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  460. Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part I—Anticardiolipin and Anti-β2-Glycoprotein I Antibodies

    Article • Seminars in Thrombosis and Hemostasis, May 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  461. Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part II—Lupus Anticoagulant

    Article • Seminars in Thrombosis and Hemostasis, May 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  462. Diagnosis of von Willebrand Disease

    Article • April 2012, Wiley

    Dr Emmanuel J Favaloro

  463. Evaluating laboratory approaches to the identification of lupus anticoagulants: A diagnostic challenge from the RCPA Haematology QAP

    Article • Pathology, April 2012, Elsevier

    Dr Emmanuel J Favaloro

  464. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity

    Article • Blood Coagulation & Fibrinolysis, April 2012, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  465. Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations

    Article • Internal Medicine Journal, April 2012, Wiley

    Dr Emmanuel J Favaloro

  466. Biological therapies for von Willebrand disease

    Article • Expert Opinion on Biological Therapy, March 2012, Informa Healthcare

    Dr Emmanuel J Favaloro

  467. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part VI

    Article • Seminars in Thrombosis and Hemostasis, March 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  468. Coffee Intake and Cardiovascular Disease: Virtue Does Not Take Center Stage

    Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  469. Hemostatic Properties of the Lymph: Relationships with Occlusion and Thrombosis

    Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  470. Hot Topics III

    Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  471. Welcome to Seminars in Thrombosis & Hemostasis 2012

    Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  472. 2B or not 2B? Masquerading as von Willebrand disease?

    Article • Journal of Thrombosis and Haemostasis, February 2012, Elsevier

    Dr Emmanuel J Favaloro

  473. Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis

    Article • Laboratory Medicine, February 2012, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  474. The new oral anticoagulants and the future of haemostasis laboratory testing

    Article • Biochemia Medica, January 2012, Croatian Society for Medical Biochemistry and Laboratory Medicine

    Dr Emmanuel J Favaloro

  475. Proficiency testing/external quality assurance for the PFA-100®

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2012, De Gruyter

    Dr Emmanuel J Favaloro

  476. Influence of mechanical trauma of blood and hemolysis on PFA-100 testing

    Article • Blood Coagulation & Fibrinolysis, January 2012, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  477. Biomedical research platforms and their influence on article submissions and journal rankings: An update

    Article • Biochemia Medica, January 2012, Croatian Society for Medical Biochemistry and Laboratory Medicine

    Dr Emmanuel J Favaloro

  478. Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies

    Article • Clinica Chimica Acta, January 2012, Elsevier

    Dr Emmanuel J Favaloro

  479. International consensus guidelines on anticardiolipin and anti–β2‐glycoprotein I testing: Report from the 13th International Congress on Antiphospholipid Antibodies

    Article • Arthritis & Rheumatism, December 2011, Wiley

    Dr Emmanuel J Favaloro

  480. Antisense therapy in the treatment of hypercholesterolemia

    Article • European Journal of Internal Medicine, December 2011, Elsevier

    Dr Emmanuel J Favaloro

  481. Laboratory testing of anticoagulants: the present and the future

    Article • Pathology, December 2011, Elsevier

    Dr Emmanuel J Favaloro

  482. A robust method for testing urinary iodine using a microtitre robotic system

    Article • Journal of Trace Elements in Medicine and Biology, December 2011, Elsevier

    Dr Emmanuel J Favaloro

  483. Iodine Deficiency: Current Aspects and Future Prospects

    Article • Laboratory Medicine, December 2011, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  484. Direct-to-consumer testing: more risks than opportunities

    Article • International Journal of Clinical Practice, November 2011, Hindawi Publishing Corporation

    Dr Emmanuel J Favaloro

  485. Holiday Thrombosis

    Article • Seminars in Thrombosis and Hemostasis, November 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  486. Seminars in Thrombosis & Hemostasis 2010: Impact Factor and Highest-Cited Articles from 2008 to 2009

    Article • Seminars in Thrombosis and Hemostasis, November 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  487. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations. Part V.

    Article • Seminars in Thrombosis and Hemostasis, November 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  488. Diagnosis and classification of von Willebrand disease

    Article • Blood Coagulation & Fibrinolysis, October 2011, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  489. von Willebrand Factor Assay Proficiency Testing Continued

    Article • American Journal of Clinical Pathology, September 2011, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  490. Thrombocytopenic Platelet Disorders

    Article • Seminars in Thrombosis and Hemostasis, September 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  491. Diagnosis of type 1 vs. 2A and 2M von Willebrand disease

    Article • Haemophilia, August 2011, Wiley

    Dr Emmanuel J Favaloro

  492. Cycling: To Race or to Live – Reflections on Skewed Priorities?

    Article • International Journal of Sports Medicine, August 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  493. Distinguishing types 1 and 2M von Willebrand disease

    Article • International Journal of Laboratory Hematology, July 2011, Wiley

    Dr Emmanuel J Favaloro

  494. Diagnosis and Management of v on Willebrand Disease in Australia

    Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  495. von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder

    Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  496. 2011 Eberhard F. Mammen Award Announcements

    Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  497. Michael Dawson, B. Pharm. (Hon), Ph.D. (1954–2010)

    Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  498. v on Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder

    Article • Seminars in Thrombosis and Hemostasis, July 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  499. Assessment for antithrombin deficiency in the real world

    Article • International Journal of Laboratory Hematology, June 2011, Wiley

    Dr Emmanuel J Favaloro

  500. Regulation of in vitro diagnostics (IVDs) for use in Australian pathology laboratories: a gloomy outlook for future pathology testing in this country?

    Article • Pathology, June 2011, Elsevier

    Dr Emmanuel J Favaloro

  501. Inherited disorders of blood coagulation

    Article • Annals of Medicine, May 2011, Taylor & Francis

    Dr Emmanuel J Favaloro

  502. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2011, De Gruyter

    Dr Emmanuel J Favaloro

  503. Laboratory diagnostics and appropriate care of people with haemophilia

    Article • Haemophilia, April 2011, Wiley

    Dr Emmanuel J Favaloro

  504. Inherited and acquired factor V deficiency

    Article • Blood Coagulation & Fibrinolysis, April 2011, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  505. A clinical audit of congenital thrombophilia investigation in tertiary practice

    Article • Pathology, April 2011, Elsevier

    Dr Emmanuel J Favaloro

  506. External quality assurance for the PFA‐100®

    Article • Journal of Thrombosis and Haemostasis, April 2011, Elsevier

    Dr Emmanuel J Favaloro

  507. Prevention of Venous Thromboembolism: Focus on Mechanical Prophylaxis

    Article • Seminars in Thrombosis and Hemostasis, March 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  508. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part IV

    Article • Seminars in Thrombosis and Hemostasis, March 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  509. Obstructive Sleep Apnea Syndrome and Cardiovascular Diseases

    Article • Seminars in Thrombosis and Hemostasis, March 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  510. Laboratory Diagnosis of von Willebrand Disease: The Phenotype

    Article • March 2011, Wiley

    Dr Emmanuel J Favaloro

  511. Frequency of Platelet type versus Type 2B von Willebrand Disease

    Article • Thrombosis and Haemostasis, February 2011, Schattauer GmbH

    Dr Margareth Castro Ozelo, Dr Emmanuel J Favaloro

  512. Venous Thromboembolism in Chronic Liver Disease

    Article • Seminars in Thrombosis and Hemostasis, February 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  513. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy

    Article • Biomarkers in Medicine, February 2011, Future Medicine

    Dr Emmanuel J Favaloro

  514. Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease

    Article • Thrombosis Research, February 2011, Elsevier

    Dr Emmanuel J Favaloro

  515. ‘Criteria’ aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010

    Article • Lupus, February 2011, SAGE Publications

    Dr Emmanuel J Favaloro

  516. More on preanalytical variables affecting platelet function testing using light transmittance aggregometry

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2011, De Gruyter

    Dr Emmanuel J Favaloro

  517. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2011, De Gruyter

    Dr Emmanuel J Favaloro

  518. Hormones, Endocrine Disorders, and Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, January 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  519. The Spectrum of Coagulation Abnormalities in Thyroid Disorders

    Article • Seminars in Thrombosis and Hemostasis, January 2011, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  520. Rethinking the diagnosis of von Willebrand disease

    Article • Thrombosis Research, January 2011, Elsevier

    Dr Emmanuel J Favaloro

  521. Coagulation update: What's new in hemostasis testing?

    Article • Thrombosis Research, January 2011, Elsevier

    Dr Emmanuel J Favaloro

  522. Regulation of in vitro diagnostics (IVDs) for use in clinical diagnostic laboratories: towards the light or dark in clinical laboratory testing?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2011, De Gruyter

    Dr Emmanuel J Favaloro

  523. Interaction of factor VIII and von Willebrand factor and the identification of type 2N von Willebrand disease

    Article • Thrombosis Research, January 2011, Elsevier

    Dr Emmanuel J Favaloro

  524. Studies on in vitro hemolysis and utility of corrective formulas for reporting results on hemolyzed specimens

    Article • Biochemia Medica, January 2011, Croatian Society for Medical Biochemistry and Laboratory Medicine

    Dr Emmanuel J Favaloro

  525. Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas

    Article • Journal of Thrombosis and Haemostasis, January 2011, Elsevier

    Dr Emmanuel J Favaloro

  526. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required

    Article • Journal of Thrombosis and Haemostasis, December 2010, Elsevier

    Dr Emmanuel J Favaloro

  527. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay

    Article • Journal of Thrombosis and Haemostasis, December 2010, Elsevier

    Dr Emmanuel J Favaloro

  528. Farewell to 2010!

    Article • Seminars in Thrombosis and Hemostasis, November 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  529. Discard Tubes Are Sometimes Necessary When Drawing Samples for HemostasisThe Authors’ Reply

    Article • American Journal of Clinical Pathology, November 2010, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  530. Article • Seminars in Thrombosis and Hemostasis, November 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  531. Global Hemostasis: New Approaches to Patient Diagnosis and Treatment Monitoring

    Article • Seminars in Thrombosis and Hemostasis, October 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  532. Winners of the 2010 Eberhard F. Mammen Award for Most Popular Article during 2008–2009

    Article • Seminars in Thrombosis and Hemostasis, October 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  533. Hemolytic Uremic Syndrome

    Article • Seminars in Thrombosis and Hemostasis, September 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  534. C-reactive protein and venous thromboembolism: causal or casual association?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), August 2010, De Gruyter

    Dr Emmanuel J Favaloro

  535. Recombinants in Thrombosis and Hemostasis: From Basic Research to Clinical Therapy

    Article • Seminars in Thrombosis and Hemostasis, July 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  536. Recombinant Platelet Factor 4: A Therapeutic, Anti-Neoplastic Chimera?

    Article • Seminars in Thrombosis and Hemostasis, July 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  537. 2009 Eberhard F. Mammen Young Investigator Award Winners

    Article • Seminars in Thrombosis and Hemostasis, July 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  538. Thrombotic Complications of Erythropoiesis-Stimulating Agents

    Article • Seminars in Thrombosis and Hemostasis, July 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  539. Shortened activated partial thromboplastin time: causes and management

    Article • Blood Coagulation & Fibrinolysis, July 2010, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  540. Quality issues in laboratory haemostasis

    Article • Haemophilia, June 2010, Wiley

    Dr Emmanuel J Favaloro

  541. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia

    Article • Haemophilia, June 2010, Wiley

    Dr Emmanuel J Favaloro

  542. Laboratory Testing in Disseminated Intravascular Coagulation

    Article • Seminars in Thrombosis and Hemostasis, June 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  543. Laboratory testing in pharmacies

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2010, De Gruyter

    Dr Emmanuel J Favaloro

  544. Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2010, De Gruyter

    Dr Emmanuel J Favaloro

  545. UNSUSPECTED COAGULOPATHY RARELY PREVENTS IV THROMBOLYSIS IN ACUTE ISCHEMIC STROKE

    Article • Neurology, May 2010, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  546. Laboratory medicine and natural disasters: are we ready for the challenge?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), May 2010, De Gruyter

    Dr Emmanuel J Favaloro

  547. The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?

    Article • Autoimmunity Highlights, May 2010, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  548. Problems in laboratory testing: hemophilia and beyond

    Article • Journal of Thrombosis and Haemostasis, May 2010, Elsevier

    Dr Emmanuel J Favaloro

  549. Under-Recognized Significance of Endothelial Heterogeneity: Hemostasis, Thrombosis, and Beyond

    Article • Seminars in Thrombosis and Hemostasis, April 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  550. Proteomic analysis of venous thromboembolism

    Article • Expert Review of Proteomics, April 2010, Taylor & Francis

    Dr Emmanuel J Favaloro

  551. Genetic testing in von Willebrand disease: reply to rebuttal

    Article • Journal of Thrombosis and Haemostasis, April 2010, Elsevier

    Dr Emmanuel J Favaloro

  552. Prevalence of hypokalaemia: the experience of a large academic hospital

    Article • Internal Medicine Journal, April 2010, Wiley

    Dr Emmanuel J Favaloro

  553. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future

    Article • Journal of Thrombosis and Thrombolysis, March 2010, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  554. Platelets, Inflammation and Cardiovascular Diseases. New Concepts and Therapeutic Implications

    Article • Seminars in Thrombosis and Hemostasis, March 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  555. A laboratory evaluation into the short activated partial thromboplastin time

    Article • Blood Coagulation & Fibrinolysis, March 2010, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  556. Mild hemophilia A

    Article • Journal of Thrombosis and Haemostasis, March 2010, Elsevier

    Dr Emmanuel J Favaloro

  557. Contemporary platelet function testing

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), February 2010, De Gruyter

    Dr Emmanuel J Favaloro

  558. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part III

    Article • Seminars in Thrombosis and Hemostasis, February 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  559. Influenza and Cardiovascular Disease: Does Swine-Origin, 2009 H1N1 Flu Virus Represent a Risk Factor, an Acute Trigger, or Both?

    Article • Seminars in Thrombosis and Hemostasis, February 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  560. Moderate Red Wine Consumption and Cardiovascular Disease Risk: Beyond the “French Paradox”

    Article • Seminars in Thrombosis and Hemostasis, February 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  561. Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample

    Article • International Journal of Laboratory Hematology, February 2010, Wiley

    Dr Emmanuel J Favaloro

  562. Quality in coagulation and haemostasis testing

    Article • Biochemia Medica, January 2010, Croatian Society for Medical Biochemistry and Laboratory Medicine

    Dr Emmanuel J Favaloro

  563. Hemophilia, cancer and cardiovascular disease

    Article • Blood Coagulation & Fibrinolysis, January 2010, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  564. Glanzmann thrombasthenia: An update

    Article • Clinica Chimica Acta, January 2010, Elsevier

    Dr Emmanuel J Favaloro

  565. Genetic testing for von Willebrand disease: the case against

    Article • Journal of Thrombosis and Haemostasis, January 2010, Elsevier

    Dr Emmanuel J Favaloro

  566. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease

    Article • Thrombosis and Haemostasis, January 2010, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  567. Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), December 2009, De Gruyter

    Dr Emmanuel J Favaloro

  568. Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia

    Article • Blood Coagulation & Fibrinolysis, December 2009, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  569. Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey

    Article • Pathology, December 2009, Elsevier

    Dr Emmanuel J Favaloro

  570. Emanuele Favaloro (1920–2009) and Francesca Favaloro (1922–2009)

    Article • Seminars in Thrombosis and Hemostasis, November 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  571. Farewell to 2009!

    Article • Seminars in Thrombosis and Hemostasis, November 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  572. Identification, Pathogenesis, and Treatment of Factor Inhibitors

    Article • Seminars in Thrombosis and Hemostasis, November 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  573. Investigations from External Quality Assurance Programs Reveal a High Degree of Variation in the Laboratory Identification of Coagulation Factor Inhibitors

    Article • Seminars in Thrombosis and Hemostasis, November 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  574. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article

    Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  575. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part II

    Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  576. Laboratory Investigation of Thrombophilia: The Good, the Bad, and the Ugly

    Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  577. Unsuspected Triggers of Venous Thromboembolism—Trivial or Not So Trivial?

    Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  578. Prostate-Specific Antigen, Prostate Cancer, and Disorders of Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  579. The Bidirectional Relationship of Cancer and Hemostasis and the Potential Role of Anticoagulant Therapy in Moderating Thrombosis and Cancer Spread

    Article • Seminars in Thrombosis and Hemostasis, October 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  580. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease

    Article • Blood Coagulation & Fibrinolysis, September 2009, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  581. Tirofiban and Activated Protein C Synergistically Inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from Allogeneic Islet Cells Exposure to Human Blood

    Article • Arabian archaeology and epigraphy, September 2009, Elsevier

    Dr Emmanuel J Favaloro

  582. D-Dimer Measurement and Laboratory Feedback

    Article • Journal of Emergency Medicine, July 2009, Elsevier

    Dr Emmanuel J Favaloro

  583. Laboratory assessment and perioperative management of patients on antiplatelet therapy: From the bench to the bedside

    Article • Clinica Chimica Acta, July 2009, Elsevier

    Dr Emmanuel J Favaloro

  584. Relationship between 24-h air pollution, emergency department admission and diagnosis of acute coronary syndrome

    Article • Journal of Thrombosis and Thrombolysis, June 2009, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  585. Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia‐Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program

    Article • International Journal of Laboratory Hematology, June 2009, Wiley

    Dr Emmanuel J Favaloro

  586. The role of ethnicity, age and gender in venous thromboembolism

    Article • Journal of Thrombosis and Thrombolysis, June 2009, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  587. Time to seek further clarity in the molecular analysis of von Willebrand disease?

    Article • Thrombosis and Haemostasis, June 2009, Schattauer GmbH

    Dr Emmanuel J Favaloro

  588. Rare Bleeding Disorders

    Article • Seminars in Thrombosis and Hemostasis, June 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  589. Rodger L. Bick, M.D., Ph.D., FACP (1943–2008)

    Article • Seminars in Thrombosis and Hemostasis, April 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  590. Coagulopathies and Thrombosis: Usual and Unusual Causes and Associations, Part I

    Article • Seminars in Thrombosis and Hemostasis, April 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  591. Mental Depression and Cardiovascular Disease: A Multifaceted, Bidirectional Association

    Article • Seminars in Thrombosis and Hemostasis, April 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  592. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?

    Article • Thrombosis Research, April 2009, Elsevier

    Dr Emmanuel J Favaloro

  593. Internal Quality Control and External Quality Assurance of Platelet Function Tests

    Article • Seminars in Thrombosis and Hemostasis, March 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  594. Diagnostic Evaluation of Platelet Disorders: The Past, the Present, and the Future

    Article • Seminars in Thrombosis and Hemostasis, March 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  595. Welcome to the First Issue of Seminars in Thrombosis and Hemostasis for 2009

    Article • Seminars in Thrombosis and Hemostasis, February 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  596. Milestones and Perspectives in Coagulation and Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, February 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  597. Relationship between activated partial thromboplastin time, heparin and potassium levels

    Article • Diabetes Research and Clinical Practice, February 2009, Elsevier

    Dr Emmanuel J Favaloro

  598. Laboratory Diagnostics and Therapy in Thrombosis and Hemostasis: From Bedside to Bench to Bedside

    Article • Seminars in Thrombosis and Hemostasis, February 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  599. Toward a New Paradigm for the Identification and Functional Characterization of von Willebrand Disease

    Article • Seminars in Thrombosis and Hemostasis, February 2009, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  600. High Rate of Deficiency in the Amino Acids Tryptophan and Histidine in People with Wounds

    Article • Advances in Skin & Wound Care, February 2009, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  601. The missing link between genotype, phenotype and clinics

    Article • Biochemia Medica, January 2009, Croatian Society for Medical Biochemistry and Laboratory Medicine

    Dr Emmanuel J Favaloro

  602. Pharmacogenetics of vitamin K antagonists: useful or hype?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2009, De Gruyter

    Dr Emmanuel J Favaloro

  603. The Journal Impact Factor: don't expect its demise any time soon

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2009, De Gruyter

    Dr Emmanuel J Favaloro

  604. Diagnosis of von willebrand disease (VWD): towards a new paradigm for the identification and functional characterisation of VWD

    Article • Pathology, January 2009, Elsevier

    Dr Emmanuel J Favaloro

  605. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin

    Article • Blood Coagulation & Fibrinolysis, January 2009, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  606. Survey on the prevalence of hemolytic specimens in an academic hospital according to collection facility: opportunities for quality improvement

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2009, De Gruyter

    Dr Emmanuel J Favaloro

  607. Epidemiological association between fasting plasma glucose and shortened APTT

    Article • Clinical Biochemistry, January 2009, Elsevier

    Dr Emmanuel J Favaloro

  608. Laboratory Evaluation of von Willebrand Disease: Phenotypic Analysis

    Article • December 2008, Wiley

    Dr Emmanuel J Favaloro

  609. Aspirin ‘responsiveness’, ‘nonresponsiveness’ or ‘resistance’: a putative role for von Willebrand factor?

    Article • Blood Coagulation & Fibrinolysis, December 2008, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  610. Welcome to a Special Issue of Seminars in Thrombosis and Hemostasis —The Closing Issue for 2008

    Article • Seminars in Thrombosis and Hemostasis, November 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  611. A Tribute to Eberhard F. Mammen, M.D. (1930–2008)

    Article • Seminars in Thrombosis and Hemostasis, November 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  612. Clinical Utility of the PFA-100

    Article • Seminars in Thrombosis and Hemostasis, November 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  613. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal

    Article • Journal of Thrombosis and Haemostasis, November 2008, Elsevier

    Dr Emmanuel J Favaloro

  614. Activated Partial Thromboplastin Time: New Tricks for an Old Dogma

    Article • Seminars in Thrombosis and Hemostasis, October 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  615. Laboratory Diagnostics in Thrombosis and Hemostasis: The Past, the Present, and the Future

    Article • Seminars in Thrombosis and Hemostasis, October 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  616. Standardization of the INR: How Good Is Your Laboratory's INR and Can It Be Improved?

    Article • Seminars in Thrombosis and Hemostasis, October 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  617. Preanalytical and Postanalytical Variables: The Leading Causes of Diagnostic Error in Hemostasis?

    Article • Seminars in Thrombosis and Hemostasis, October 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  618. Dark chocolate: consumption for pleasure or therapy?

    Article • Journal of Thrombosis and Thrombolysis, September 2008, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  619. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients

    Article • Journal of Thrombosis and Thrombolysis, September 2008, Springer Science + Business Media

    Dr Emmanuel J Favaloro

  620. Salbutamol in Athletes

    Article • Clinical Journal of Sport Medicine, September 2008, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  621. Genetics of type 2B von Willebrand Disease: “True 2B,” “tricky 2B,” or “Not 2B.” What Are the Modifiers of the Phenotype?

    Article • Seminars in Thrombosis and Hemostasis, September 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  622. A better approach to monitoring of therapy in von Willebrand disease?

    Article • Thrombosis and Haemostasis, August 2008, Schattauer GmbH

    Dr Emmanuel J Favaloro

  623. Updates on improvement of human athletic performance: focus on world records in athletics

    Article • British Medical Bulletin, August 2008, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  624. Differential identification of PT‐VWD from type 2B VWD and GP1BA nomenclature issues response to Othman

    Article • British Journal of Haematology, June 2008, Wiley

    Dr Emmanuel J Favaloro

  625. The genetic basis of human athletic performance. Why are psychological components so often overlooked?

    Article • The Journal of Physiology, June 2008, Wiley

    Dr Emmanuel J Favaloro

  626. Antiphospholipid Antibodies and the Antiphospholipid Syndrome II: Limitations, Standardization, and Clinical Utility of Laboratory Testing

    Article • Seminars in Thrombosis and Hemostasis, June 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  627. Laboratory Testing and Identification of Antiphospholipid Antibodies and the Antiphospholipid Syndrome: A Potpourri of Problems, a Compilation of Possible Solutions

    Article • Seminars in Thrombosis and Hemostasis, June 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  628. A Consensus Approach to the Formulation of Guidelines for Laboratory Testing and Reporting of Antiphospholipid Antibody Assays

    Article • Seminars in Thrombosis and Hemostasis, June 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  629. The paradoxical relationship between serum uric acid and cardiovascular disease

    Article • Clinica Chimica Acta, June 2008, Elsevier

    Dr Emmanuel J Favaloro

  630. Article • Seminars in Thrombosis and Hemostasis, June 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  631. Cardiac biomarkers in pulmonary embolism

    Article • Thrombosis and Haemostasis, May 2008, Schattauer GmbH

    Dr Emmanuel J Favaloro

  632. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature: Only a part of the story

    Article • Thrombosis and Haemostasis, May 2008, Schattauer GmbH

    Dr Emmanuel J Favaloro

  633. Potential benefits of improved protein intake in older people

    Article • Nutrition & Dietetics, May 2008, Wiley

    Dr Emmanuel J Favaloro

  634. Clinical Features, Diagnosis, and Management of the Antiphospholipid Syndrome

    Article • Seminars in Thrombosis and Hemostasis, April 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  635. Professor Ronald A. Asherson, M.D. (Hon), F.R.C.P., M.D., F.A.C.P., F.C.P., F.A.C.R., Dip. O&G (Hon) [1934–2008]

    Article • Seminars in Thrombosis and Hemostasis, April 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  636. Antiphospholipid Antibodies and the Antiphospholipid Syndrome I: Pathogenesis, Clinical Features, Diagnosis, and Management

    Article • Seminars in Thrombosis and Hemostasis, April 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  637. The LOC387715 Polymorphism, Inflammatory Markers, Smoking, and Age-Related Macular Degeneration

    Article • Ophthalmology, April 2008, Elsevier

    Dr Emmanuel J Favaloro

  638. Time to think outside the box? Prothrombin time, international normalised ratio, international sensitivity index, mean normal prothrombin time and measurement of uncertainty a novel approach to standardisation

    Article • Pathology, April 2008, Elsevier

    Dr Emmanuel J Favaloro

  639. Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1–3?

    Article • Journal of Thrombosis and Haemostasis, March 2008, Elsevier

    Dr Emmanuel J Favaloro

  640. von Willebrand disease, type 2B: A diagnosis more elusive than previously thought

    Article • Thrombosis and Haemostasis, February 2008, Schattauer GmbH

    Dr Emmanuel J Favaloro

  641. Welcome to Seminars in Thrombosis and Hemostasis -2008!

    Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  642. Measuring the Quality of Journals and Journal Articles: The Impact Factor Tells but a Portion of the Story

    Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  643. Hot Topics II: An Editorial Collection of Current Issues and Controversies in Thrombosis and Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  644. Phenotypic Identification of Platelet-Type von Willebrand Disease and Its Discrimination from Type 2B von Willebrand Disease: A Question of 2B or Not 2B? A Story of Nonidentical Twins? Or Two Sides of a Multidenominational or Multifaceted Primary-Hemos...

    Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  645. Detection of duplicates and redundancies. A major responsibility of peer-reviewers?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2008, De Gruyter

    Dr Emmanuel J Favaloro

  646. Help me, Doctor! My D-dimer is raised

    Article • Annals of Medicine, January 2008, Taylor & Francis

    Dr Emmanuel J Favaloro

  647. Protein Z is reduced in chronic kidney disease and not elevated in patients on haemodialysis

    Article • Blood Coagulation & Fibrinolysis, January 2008, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  648. Air pollution and coagulation testing: A new source of biological variability?

    Article • Thrombosis Research, January 2008, Elsevier

    Dr Emmanuel J Favaloro

  649. A practical approach to instrument selection, evaluation, basic financial management and implementation in pathology and research

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2008, De Gruyter

    Dr Emmanuel J Favaloro

  650. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting

    Article • Pathology, January 2008, Elsevier

    Dr Emmanuel J Favaloro

  651. The Diagnostic Dilemma: Dual Presentations of Clinical Mucosal Bleeding and Venous Thrombosis Associated with the Presence of Thrombophilia Markers and Mild Reduction in von Willebrand Factor

    Article • Laboratory Hematology, December 2007, Carden Jennings Publishing Co.

    Dr Emmanuel J Favaloro

  652. Hot Topics I: A Potpourri of Current Issues and Controversies in Thrombosis and Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, November 2007, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  653. An Update on the von Willebrand Factor Collagen Binding Assay: 21 Years of Age and Beyond Adolescence but Not Yet a Mature Adult

    Article • Seminars in Thrombosis and Hemostasis, November 2007, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  654. Hemostatic Dysfunction Associated with Endocrine Disorders as a Major Risk Factor and Cause of Human Morbidity and Mortality: A Comprehensive Meta-review

    Article • Seminars in Thrombosis and Hemostasis, November 2007, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  655. Time to Think Outside the Box? Proposals for a New Approach to Future Pharmacokinetic Studies of von Willebrand Factor Concentrates in People with von Willebrand Disease

    Article • Seminars in Thrombosis and Hemostasis, November 2007, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  656. Differential identification of a rare form of platelet‐type (pseudo‐) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin‐induced‐platelet‐agglutination mixing assay and confirmed by genetic analysis

    Article • British Journal of Haematology, October 2007, Wiley

    Dr Emmanuel J Favaloro

  657. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation

    Article • Pathology, October 2007, Elsevier

    Dr Emmanuel J Favaloro

  658. More on the impact factor and thrombosis and haemostasis journals: Benefits and limitations

    Article • Thrombosis and Haemostasis, July 2007, Schattauer GmbH

    Dr Emmanuel J Favaloro

  659. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD

    Article • Thrombosis and Haemostasis, July 2007, Schattauer GmbH

    Dr Emmanuel J Favaloro

  660. Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand

    Article • Blood Coagulation & Fibrinolysis, July 2007, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  661. Circulating Inflammatory Markers and Hemostatic Factors in Age-Related Maculopathy: A Population-Based Case–Control Study

    Article • Investigative Ophthalmology & Visual Science, May 2007, Association for Research in Vision and Ophthalmology (ARVO)

    Dr Emmanuel J Favaloro

  662. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study

    Article • Thrombosis and Haemostasis, April 2007, Schattauer GmbH

    Dr Emmanuel J Favaloro

  663. Standardization, Quality Assurance, and Emerging Diagnostic Technologies in Hemostasis

    Article • Seminars in Thrombosis and Hemostasis, April 2007, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  664. Emerging Technologies and Quality Assurance in Hemostasis: A Review of Findings from the Royal College of Pathologists of Australasia Quality Assurance Program

    Article • Seminars in Thrombosis and Hemostasis, April 2007, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  665. Standardization, Regulation, Quality Assurance and Emerging Technologies in Hemostasis: Issues, Controversies, Benefits, and Limitations

    Article • Seminars in Thrombosis and Hemostasis, April 2007, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  666. A Review of β 2 -Glycoprotein-I Antibody Testing Results From a Peer-Driven Multilaboratory Quality Assurance Program

    Article • American Journal of Clinical Pathology, March 2007, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  667. Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?

    Article • Haematologica, March 2007, Ferrata Storti Foundation (Haematologica)

    Dr Emmanuel J Favaloro

  668. Erratum

    Article • British Journal of Haematology, March 2007, Wiley

    Dr Emmanuel J Favaloro

  669. Preanalytical variables in coagulation testing

    Article • Blood Coagulation & Fibrinolysis, January 2007, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  670. Thrombophilia and Cerebral Vein Thrombosis

    Article • January 2007, Karger Publishers

    Dr Emmanuel J Favaloro

  671. Increased Propensity to Bruising in Red-Haired Females: A Possible Role for von Willebrand Factor?

    Article • Anesthesia & Analgesia, December 2006, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  672. 2B or not 2B? Differential identification of type 2B, versus pseudo‐, von Willebrand disease – response to Whalley and Perry

    Article • British Journal of Haematology, November 2006, Wiley

    Dr Emmanuel J Favaloro

  673. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

    Article • Journal of Thrombosis and Haemostasis, October 2006, Elsevier

    Dr Emmanuel J Favaloro

  674. Laboratory Monitoring of Therapy in von Willebrand Disease: Efficacy of the PFA-100 and von Willebrand Factor:Collagen-Binding Activity as Coupled Strategies

    Article • Seminars in Thrombosis and Hemostasis, September 2006, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  675. More on: platelet function analyser (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function

    Article • Journal of Thrombosis and Haemostasis, September 2006, Elsevier

    Dr Emmanuel J Favaloro

  676. Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto‐antibodies to von Willebrand factor

    Article • Journal of Thrombosis and Haemostasis, September 2006, Elsevier

    Dr Emmanuel J Favaloro

  677. 2B or not 2B? Differential identification of type 2B, versus pseudo‐von Willebrand disease

    Article • British Journal of Haematology, August 2006, Wiley

    Dr Emmanuel J Favaloro

  678. Laboratory Identification of von Willebrand Disease: Technical and Scientific Perspectives

    Article • Seminars in Thrombosis and Hemostasis, July 2006, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  679. The Utility of the PFA-100 in the Identification of von Willebrand Disease: A Concise Review

    Article • Seminars in Thrombosis and Hemostasis, July 2006, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  680. Reducing Errors in Identification of von Willebrand Disease: The Experience of the Royal College of Pathologists of Australasia Quality Assurance Program

    Article • Seminars in Thrombosis and Hemostasis, July 2006, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  681. More on ‘universal’versus‘selected’ screening for thrombophilia: the hidden costs of false‐positive diagnosis

    Article • British Journal of Haematology, June 2006, Wiley

    Dr Emmanuel J Favaloro

  682. Identification of factor inhibitors by diagnostic haemostasis laboratories. A large multi-centre evaluation

    Article • Thrombosis and Haemostasis, June 2006, Schattauer GmbH

    Dr Emmanuel J Favaloro

  683. Unrecognized pellagra masquerading as odynophagia

    Article • Internal Medicine Journal, June 2006, Wiley

    Dr Emmanuel J Favaloro

  684. Abstracts from the 24th Annual Scientific Meeting

    Article • Immunology and Cell Biology, June 2006, Wiley

    Dr Emmanuel J Favaloro

  685. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti‐β2‐glycoprotein‐1 ELISAs: a rebuttal

    Article • Journal of Thrombosis and Haemostasis, June 2006, Elsevier

    Dr Emmanuel J Favaloro

  686. Effect of overnight 4°C storage of whole blood on von Willebrand factor

    Article • Transfusion, May 2006, Wiley

    Dr Emmanuel J Favaloro

  687. 2B or not 2B? What is the role of VWF in platelet–matrix interactions? And what is the role of the VWF:CB in VWD diagnostics? These are the questions

    Article • Journal of Thrombosis and Haemostasis, April 2006, Elsevier

    Dr Emmanuel J Favaloro

  688. Activated protein C resistance: The influence of ABO-blood group, gender and age

    Article • Thrombosis Research, January 2006, Elsevier

    Dr Emmanuel J Favaloro

  689. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease

    Article • Blood Coagulation & Fibrinolysis, January 2006, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  690. Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder

    Article • American Journal of Clinical Pathology, December 2005, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  691. Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder

    Article • American Journal of Clinical Pathology, December 2005, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  692. Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors

    Article • Blood Coagulation & Fibrinolysis, November 2005, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  693. How Useful is the Monitoring of (Low Molecular Weight) Heparin Therapy by Anti-Xa Assay? A Laboratory Perspective

    Article • Laboratory Hematology, September 2005, Carden Jennings Publishing Co.

    Dr Emmanuel J Favaloro

  694. Laboratory Identification of Familial Thrombophilia: Do the Pitfalls Exceed the Benefits? A Reassessment of ABO-Blood Group, Gender,Age, and other Laboratory Parameters on the Potential Influence on a Diagnosis of Protein C, Protein S, and Antithromb

    Article • Laboratory Hematology, September 2005, Carden Jennings Publishing Co.

    Dr Emmanuel J Favaloro

  695. A Diet Rich in High-Oleic-Acid Sunflower Oil Favorably Alters Low-Density Lipoprotein Cholesterol, Triglycerides, and Factor VII Coagulant Activity

    Article • Journal of the American Dietetic Association, July 2005, Elsevier

    Dr Emmanuel J Favaloro

  696. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin

    Article • Pathology, June 2005, Elsevier

    Dr Emmanuel J Favaloro

  697. Laboratory Diagnosis of von Willebrand Disorder: Use of Multiple Functional Assays Reduces Diagnostic Error Rates

    Article • Laboratory Hematology, June 2005, Carden Jennings Publishing Co.

    Dr Emmanuel J Favaloro

  698. Diagnostic Issues in Thrombophilia: A Laboratory Scientist's View

    Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  699. External Quality Assurance of DNA Testing for Thrombophilia Mutations

    Article • American Journal of Clinical Pathology, February 2005, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  700. Development of Consensus Guidelines for Anticardiolipin and Lupus Anticoagulant Testing

    Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  701. Learning from Peer Assessment: The Role of the External Quality Assurance Multilaboratory Thrombophilia Test Process

    Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  702. Multilaboratory Testing of Thrombophilia: Current and Past Practice in Australasia as Assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology

    Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  703. A Multilaboratory Peer Assessment Quality Assurance Program-Based Evaluation of Anticardiolipin Antibody, and beta 2 -Glycoprotein I Antibody Testing

    Article • Seminars in Thrombosis and Hemostasis, February 2005, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  704. Is elevated factor VIII a risk factor for venous thromboembolism in Canada?

    Article • Thrombosis and Haemostasis, January 2005, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  705. Factor V inhibitors

    Article • Blood Coagulation & Fibrinolysis, December 2004, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  706. Template bleeding time and PFA‐100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients – a rebuttal

    Article • Journal of Thrombosis and Haemostasis, December 2004, Elsevier

    Dr Emmanuel J Favaloro

  707. Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing

    Article • American Journal of Clinical Pathology, November 2004, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  708. Potential Laboratory Misdiagnosis of Hemophilia and von Willebrand Disorder Owing to Cold Activation of Blood Samples for Testing

    Article • American Journal of Clinical Pathology, November 2004, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  709. Evaluation of primary haemostasis in people with neurofibromatosis type 1

    Article • International Journal of Laboratory Hematology, October 2004, Wiley

    Dr Emmanuel J Favaloro

  710. von Willebrand disease: laboratory aspects of diagnosis and treatment

    Article • Haemophilia, October 2004, Wiley

    Dr Emmanuel J Favaloro

  711. Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process

    Article • Haemophilia, April 2004, Wiley

    Dr Emmanuel J Favaloro

  712. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays

    Article • Pathology, April 2004, Elsevier

    Dr Emmanuel J Favaloro

  713. Consensus guidelines on anti-cardiolipin antibody testing and reporting

    Article • Pathology, February 2004, Elsevier

    Dr Emmanuel J Favaloro

  714. Laboratory Diagnosis of von Willebrand Disorder

    Article • American Journal of Clinical Pathology, June 2003, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  715. Laboratory Diagnosis of von Willebrand Disorder: Current Practice in the Southern Hemisphere

    Article • American Journal of Clinical Pathology, June 2003, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  716. A duplex issue: (i) time to re‐appraise the diagnosis and classification of von Willebrand disorder, and (ii) clarification of the roles of von Willebrand factor collagen binding and ristocetin cofactor activity assays

    Article • Haemophilia, November 2002, Wiley

    Dr Emmanuel J Favaloro

  717. Assessing the Usefulness of Anticardiolipin Antibody Assays

    Article • American Journal of Clinical Pathology, October 2002, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  718. Clinical application of the PFA-100®

    Article • Current Opinion in Hematology, September 2002, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  719. Identification of von Willebrand Disease Type 2N (Normandy) in Australia

    Article • American Journal of Clinical Pathology, August 2002, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  720. Treatment of two patients with acquired factor VIII inhibitors using cyclophosphamide and prednisone

    Article • American Journal of Hematology, July 2002, Wiley

    Dr Emmanuel J Favaloro

  721. von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey

    Article • Seminars in Thrombosis and Hemostasis, January 2002, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  722. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations

    Article • Pathology, January 2002, Elsevier

    Dr Emmanuel J Favaloro

  723. Nitric Oxide and Prostacyclin are Released by Cultured Apoptotic Human Umbilical Vein Endothelial Cells Consistent with an Anti-Micro-Thrombotic Potential

    Article • Thrombosis and Haemostasis, January 2002, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  724. A Comparative Multi-laboratory Assessment of Three Factor VIII/von Willebrand Factor Concentrates

    Article • Thrombosis and Haemostasis, January 2002, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  725. Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder

    Article • Best Practice & Research Clinical Haematology, June 2001, Elsevier

    Dr Emmanuel J Favaloro

  726. Utility of the PFA‐100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations

    Article • Haemophilia, March 2001, Wiley

    Dr Emmanuel J Favaloro

  727. Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor

    Article • American Journal of Hematology, January 2001, Wiley

    Dr Emmanuel J Favaloro

  728. Human Endothelial Cells Maintain Anti-Aggregatory Activity for Platelets during Apoptosis

    Article • Thrombosis and Haemostasis, January 2001, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  729. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey

    Article • Blood Coagulation & Fibrinolysis, December 2000, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  730. Detection of von Willebrand Disorder and Identification of Qualitative von Willebrand Factor Defects Direct Comparison of Commercial ELISA-Based von Willebrand Factor Activity Options

    Article • American Journal of Clinical Pathology, October 2000, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  731. Is the activity of VWF increased in type II diabetes mellitus?

    Article • Diabetes Research and Clinical Practice, September 2000, Elsevier

    Dr Emmanuel J Favaloro

  732. Sulfatide-Binding Assay for von Willebrand Factor

    Article • Thrombosis Research, April 2000, Elsevier

    Dr Emmanuel J Favaloro

  733. Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: Phenotype and genotype correlations

    Article • American Journal of Hematology, April 2000, Wiley

    Dr Emmanuel J Favaloro

  734. Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor

    Article • American Journal of Hematology, January 2000, Wiley

    Dr Emmanuel J Favaloro

  735. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation

    Article • Blood, January 2000, American Society of Hematology

    Dr Emmanuel J Favaloro

  736. Collagen Binding Assay for von Willebrand Factor (VWF:CBA): Detection of von Willebrands Disease (VWD), and Discrimination of VWD Subtypes, Depends on Collagen Source

    Article • Thrombosis and Haemostasis, January 2000, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  737. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand’s disease

    Article • Blood Reviews, December 1999, Elsevier

    Dr Emmanuel J Favaloro

  738. Use of a novel platelet function analyzer (PFA‐100™) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders

    Article • American Journal of Hematology, November 1999, Wiley

    Dr Emmanuel J Favaloro

  739. Use of a novel platelet function analyzer (PFA-100?) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders

    Article • American Journal of Hematology, November 1999, Wiley

    Dr Emmanuel J Favaloro

  740. Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V leiden and prothrombin G20210A

    Article • American Journal of Hematology, November 1999, Wiley

    Dr Emmanuel J Favaloro

  741. Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V leiden and prothrombin G20210A

    Article • American Journal of Hematology, November 1999, Wiley

    Dr Emmanuel J Favaloro

  742. Laboratory Testing, Diagnosis, and Management of von Willebrand Disease: Current Practice in Australasia

    Article • American Journal of Clinical Pathology, November 1999, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  743. Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease

    Article • British Journal of Haematology, May 1999, Wiley

    Dr Emmanuel J Favaloro

  744. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach

    Article • Pathology, January 1999, Elsevier

    Dr Emmanuel J Favaloro

  745. Comparison of the effects of two low fat diets with different α-linolenic:linoleic acid ratios on coagulation and fibrinolysis

    Article • Atherosclerosis, January 1999, Elsevier

    Dr Emmanuel J Favaloro

  746. A Novel Factor V Null Mutation at Arg 506 Causes a False Positive Factor V Leiden Result

    Article • Thrombosis and Haemostasis, January 1999, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  747. Laboratory Testing for von Willebrand’s Disease: An Assessment of Current Diagnostic Practice and Efficacy by Means of a Multi-laboratory Survey

    Article • Thrombosis and Haemostasis, January 1999, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  748. Type 2B von Willebrand’s Disease and Angiodysplasia

    Article • Thrombosis and Haemostasis, January 1999, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  749. Medical research in New South Wales 1993–1996 assessed by Medline publication capture

    Article • The Medical Journal of Australia, December 1998, Australasian Medical Publishing Co. Pty Ltd. (AMPCo)

    Dr Emmanuel J Favaloro

  750. A Simple, Whole Blood Method for Assessment of Platelet Function

    Article • Thrombosis Research, May 1998, Elsevier

    Dr Emmanuel J Favaloro

  751. Biliary fibronectin: Significant limitation as a diagnostic tool in malignant biliary obstruction

    Article • Gastroenterology, April 1998, Elsevier

    Dr Emmanuel J Favaloro

  752. Laboratory Assessment of von Willebrand Factor: Altered Interpretation of Laboratory Data, and Altered Diagnosis of von Willebrand's Disease

    Article • Clinical and Applied Thrombosis/Hemostasis, April 1997, SAGE Publications

    Dr Emmanuel J Favaloro

  753. The MDA-180 coagulation analyser: a laboratory evaluation

    Article • Pathology, January 1997, Elsevier

    Dr Emmanuel J Favaloro

  754. Laboratory assays for von Willebrand Factor: relative contribution to the diagnosis of von Willebrand’s disease

    Article • Pathology, January 1997, Elsevier

    Dr Emmanuel J Favaloro

  755. Laboratory assessment of von Willebrand factor: differential influence of prolonged ambient temperature specimen storage on assay results

    Article • Haemophilia, October 1996, Wiley

    Dr Emmanuel J Favaloro

  756. Cardiovascular Risk Factors and Dietary Plant Omega-3 Verus Omega-6 Fatty Acids

    Article • Journal of the American Dietetic Association, September 1996, Elsevier

    Dr Emmanuel J Favaloro

  757. MUTATIONS IN A SUBGROUP OF PATIENTS WITH MILD HAEMOPHILIA A AND A FAMILIAL DISCREPANCY BETWEEN THE ONE‐STAGE AND TWO‐STAGE FACTOR VIII:C METHODS

    Article • British Journal of Haematology, August 1996, Wiley

    Dr Emmanuel J Favaloro

  758. A survey of heparin monitoring in australasia

    Article • Pathology, January 1996, Elsevier

    Dr Emmanuel J Favaloro

  759. Aminopeptidase-N (CD13; gp 150): Contrasting patterns of enzymatic activity in blood from patients with myeloid or lymphoid leukemia

    Article • Leukemia Research, September 1995, Elsevier

    Dr Emmanuel J Favaloro

  760. Laboratory Assessment of von Willebrand Factor:Use of Different Assays Can Influence the Diagnosis of von Willebrand’s Disease, Dependent on Differing Sensitivity to Sample Preparation and Differential Recognition of High Molecular Weight VWF Forms

    Article • American Journal of Clinical Pathology, September 1995, Oxford University Press (OUP)

    Dr Emmanuel J Favaloro

  761. Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1

    Article • British Journal of Haematology, March 1995, Wiley

    Dr Emmanuel J Favaloro

  762. von Willebrand's disease: Use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy

    Article • American Journal of Hematology, March 1994, Wiley

    Dr Emmanuel J Favaloro

  763. Differential expression of surface antigens on activated endothelium

    Article • Immunology and Cell Biology, December 1993, Wiley

    Dr Emmanuel J Favaloro

  764. The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150

    Article • Clinica Chimica Acta, October 1993, Elsevier

    Dr Emmanuel J Favaloro

  765. Acidified Chloroquine Treatment for the Removal of Class I HLA Antigens

    Article • Vox Sanguinis, July 1993, Wiley

    Dr Emmanuel J Favaloro

  766. Von willebrand's disease: laboratory investigation using an improved functional assay for von willebrand factor

    Article • Pathology, January 1993, Elsevier

    Dr Emmanuel J Favaloro

  767. Characterization of GMP-140 (P-selectin) as a circulating plasma protein.

    Article • Journal of Experimental Medicine, April 1992, Rockefeller University Press

    Dr Emmanuel J Favaloro

  768. Heparin - induced thrombocytopenia: laboratory investigation and confirmation of diagnosis

    Article • Pathology, January 1992, Elsevier

    Dr Emmanuel J Favaloro

  769. CD‐13 (‘gp150’; aminopeptidase‐N): Co‐expression on endothelial and haemopoietic cells with conservation of functional activity

    Article • Immunology and Cell Biology, August 1991, Wiley

    Dr Emmanuel J Favaloro

  770. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand??s disease

    Article • Blood Coagulation & Fibrinolysis, April 1991, Wolters Kluwer Health

    Dr Emmanuel J Favaloro

  771. Co‐expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis

    Article • British Journal of Haematology, April 1990, Wiley

    Dr Emmanuel J Favaloro

  772. Endothelial Cells and Normal Circulating Haemopoietic Cells Share a Number of Surface Antigens

    Article • Thrombosis and Haemostasis, January 1989, Thieme Publishing Group

    Dr Emmanuel J Favaloro

  773. Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non‐haemopoietic distribution using panels of monoclonal antibodies belonging to CD‐11b, CD‐13 and CD‐33

    Article • British Journal of Haematology, June 1988, Wiley

    Dr Emmanuel J Favaloro

  774. Immunophenotype of clonogenic cells in myeloid leukaemia

    Article • Leukemia Research, January 1988, Elsevier

    Dr Emmanuel J Favaloro

  775. Further studies on the heterogeneity of antigens recognised by CD‐1 monoclonal antibodies: distribution of epitopes and analysis of serological binding patterns

    Article • Immunology and Cell Biology, December 1987, Wiley

    Dr Emmanuel J Favaloro

  776. Further studies on the heterogeneity of antigens recognised by CD‐1 monoclonal antibodies: distribution of epitopes and analysis of serological binding patterns

    Article • Immunology and Cell Biology, October 1987, Wiley

    Dr Emmanuel J Favaloro

  777. TRANSPLANTATION OF MONOCLONAL ANTIBODY‐PURGED AUTOLOGOUS BONE MARROW FOR TREATMENT OF POOR RISK COMMON ACUTE LYMPHOBLASTIC LEUKEMIA

    Article • Australian and New Zealand Journal of Medicine, June 1987, Wiley

    Dr Emmanuel J Favaloro

  778. Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: A comparison of acute myeloid leukaemia and normal bone marrow cells

    Article • American Journal of Hematology, September 1986, Wiley

    Dr Emmanuel J Favaloro

  779. Standardization of monoclonal antibodies for use in autologous bone marrow transplantation for common acute lymphoblastic leukemia

    Article • Pathology, January 1986, Elsevier

    Dr Emmanuel J Favaloro

  780. Myeloid progenitor surface antigen identified by monoclonal antibody

    Article • British Journal of Haematology, September 1985, Wiley

    Dr Emmanuel J Favaloro

  781. Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells

    Article • Pathology, January 1985, Elsevier

    Dr Emmanuel J Favaloro

  782. The role of buffer anions and protons in secretion by the rabbit mandibular salivary gland.

    Article • The Journal of Physiology, January 1982, Wiley

    Dr Emmanuel J Favaloro